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 Throughout much of history, safe and effective drug doses have been discovered 
through trial-and-error and validated via anecdote.  Such approaches are limited in their 
ability to define how a drug’s safety and effectiveness are influenced by the addition of 
other co-administered medications and the presence of other acute and/or chronic diseases.  
Consideration of all these pharmacological and pathophysiological factors is impractical 
given the complexity of the many interactions that may occur. 
To further advance clinical pharmacology, it has become necessary to leverage the 
increasing speed and storage capacity of computers.  Developments in mathematics, 
statistics, and computer science have revolutionized the field of clinical pharmacology by 
making computers far more than glorified calculators.  Today, sophisticated algorithms can 
be used to interrogate and learn from pharmacological datasets and make informed 
predictions about the safety and effectiveness of drug dosing regimens.  The goal of these 
population pharmacokinetic analyses is to yield accurate predictions of clinically-relevant 
pharmacokinetic parameters and improve our understanding of the biological processes 
that mediate drug disposition. 
In this dissertation, we present the results of three pharmacokinetic studies that 
demonstrate the clinical utility of population pharmacokinetic modelling, along the way 
challenging conventional dosing strategies for vancomycin in preterm neonates and 
zolpidem among severely burned children.  Additionally, we developed a simulation-based 
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parameter estimation algorithms.  This work lays the foundation for a transparent dialogue 
regarding the relative strengths and weaknesses of individual algorithms, which heretofore 
has not been possible.  We conclude with a discussion of the additional unanswered 
questions that may now be investigated using the benchmarking framework developed 
here. 
The results of the studies described in this dissertation underscore the importance 
of enhancing the clinical adoption of population pharmacokinetic models.  However, these 
models must be rigorously evaluated to ensure that they are unbiased and precise.  In 
simulations, three of the most commonly used pharmacokinetic parameter estimation 
algorithms differentiated themselves when they were applied in different clinical scenarios.  
This finding highlights an intriguing practical fact that algorithm selection should be 
guided by the clinical question at hand. 
  
TABLE OF CONTENTS 
 
ABSTRACT ....................................................................................................................... iii 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES .............................................................................................................x 
LIST OF ABBREVIATIONS ........................................................................................... xii 
ACKNOWLEDGEMENTS ............................................................................................. xiv 
Chapters 
1. POPULATION PHARMACOKINETIC MODELING ................................................1 
The Relationship between Clinical Trials and Population Pharmacokinetics ...............1 
Individual vs. Population Pharmacokinetics ..................................................................2 
History of Population Pharmacokinetics .......................................................................3 
General Mathematical Formulation ...............................................................................4 
Methodological Approaches Employed in Population Pharmacokinetic Analyses .......6 
Applications of Population Pharmacokinetics ...............................................................8 
Dosing Optimization ......................................................................................................9 
Statement of Objectives ...............................................................................................10 
References ....................................................................................................................12 
 
2. VANCOMYCIN PHARMACOKINETIC MODELS: INFORMING THE CLINICAL 
MANAGEMENT OF DRUG-RESISTANT BACTERIAL INFECTIONS................15 
   
Abstract ........................................................................................................................15 
Background ..................................................................................................................16 





Considerations for Pharmacokinetic Modeling .....................................................23 
Pharmacodynamic Profile ............................................................................................28 
Exposure-Response Profiles ..................................................................................28
vi 
Pharmacokinetic / Pharmacodynamic Indices .......................................................28 
Antibiotic Susceptibility Testing ...........................................................................29
Considerations for Pharmacodynamic Modeling...................................................31 
Dosing Optimization ....................................................................................................34 
AUC / MIC Targets ...............................................................................................34 
Trough Concentration Targets ...............................................................................35 
Empiric and Definitive Dosing Regimens .............................................................36 
Continuous Infusion ...............................................................................................37 
Special Populations ......................................................................................................38 
Neonates and Infants ..............................................................................................38
Children and Adolescents ......................................................................................40 
The Elderly.............................................................................................................42 
Obese Patients ........................................................................................................43 
Patients with Cancer ..............................................................................................45 
Continuous Renal Replacement Therapy...............................................................46 
Patients with Cystic Fibrosis ..................................................................................48 
Critically Ill Patients ..............................................................................................48 
Expert Commentary and Five-Year View ...................................................................50 
References ....................................................................................................................52 
 
3. POPULATION PHARMACOKINETICS OF INTERMITTENT VANCOMYCIN IN 





Setting and Study Population .................................................................................70 
Drug Administration and Sample Collection .........................................................70 
Vancomycin Assay ................................................................................................71 
Pharmacokinetic Analysis ......................................................................................71 
Covariate Analysis .................................................................................................73 
Model Evaluation ...................................................................................................74 
Results ..........................................................................................................................75 
Patients and Pharmacokinetics ...............................................................................75 
Population Pharmacokinetic Models .....................................................................75 





4. PREDICTIVE PERFORMANCE OF A VANCOMYCIN POPULATION 








Model Evaluation ...................................................................................................96 
Trough Concentrations and AUC24 Relationship ..................................................98 
Results ..........................................................................................................................99 
External Validation Cohort ....................................................................................99 
Model Evaluation ...................................................................................................99 





5. PRELIMINARY ASSESSMENT OF ZOLPIDEM PHARMACOKINETICS IN 




Materials and Methods ...............................................................................................117 
Subjects and Study Design...................................................................................117 
Drug Administration ............................................................................................117 
Sample Collection ................................................................................................118 
Analytical Assay ..................................................................................................118 
Pharmacokinetic Analysis ....................................................................................120 
Base Model Development ....................................................................................122 
Covariate Analysis ...............................................................................................122 
Model Evaluation .................................................................................................123 
Results ........................................................................................................................123 
Subjects and Pharmacokinetics ............................................................................123 
Population Pharmacokinetic Models ...................................................................124 
Covariate Models .................................................................................................124 






6. SIMULATION-BASED PHARMACOMETRIC BENCHMARKING OF 
MONOLIX, NONMEM, AND PMETRICS .............................................................139 
 
Introduction ................................................................................................................139 
Materials and Methods ...............................................................................................140 
Experimental Design ............................................................................................140 
Software Programs Tested ...................................................................................141 
Model Implementation .........................................................................................143 
Statistical Analysis ...............................................................................................144 
Results ........................................................................................................................145 
Correctly-Specified Models with Covariates .......................................................145 
viii 
 











A. VANCOMYCIN POPULATION PHARMACOKINETIC ANALYSIS 
CODE ...................................................................................................................167 
 
B. ZOLPIDEM POPULATION PHARMACOKINETIC ANALYSIS CODE .......170 
 
C. RELATIONSHIP BETWEEN ZOLPIDEM CONCENTRATIONS AND SLEEP 
PARAMETERS IN PEDIATRIC BURN PATIENTS ........................................173 
 
D. POPULATION PHARMACOKINETIC BENCHMARKING DATASETS ......182 
 
 
LIST OF TABLES 
 
Table               Page 
 
2.1. A comparison of adult vancomycin population pharmacokinetic studies ................24 
 
3.1. Demographic characteristics among children with cystic fibrosis who received 
vancomycin for the treatment of an acute pulmonary exacerbation .........................76 
 
3.2. Vancomycin pharmacokinetic parameter estimates and bootstrap estimates from the 
final one-compartment covariate model across the entire study population .............78 
 
4.1. Demographic and clinical characteristics of neonates who received vancomycin and 
had therapeutic drug monitoring performed ...........................................................100 
 
4.2. Timing of 734 neonatal vancomycin concentrations relative to the end of the most 
recent 1-h infusion ..................................................................................................101 
 
4.3. Predictive performance of the neonatal population pharmacokinetic model in the 
external validation cohort .......................................................................................104 
 
4.4. Predictive performance of the neonatal population pharmacokinetic model in the 
external validation cohort after incorporating patient drug concentrations in 
predictions (e.g., IPRED method) ...........................................................................105 
 
5.1. Demographic and clinical characteristics of severely burned children who received 
zolpidem as a sleep-enhancing agent ......................................................................119 
 
5.2. Zolpidem population pharmacokinetic parameter estimates from the final two-
compartment covariate model .................................................................................128 
 
6.1. Bias and precision of the estimated population pharmacokinetic parameter values 
obtained using Monolix, NONMEM, and Pmetrics for correctly-specified models 
with covariates ........................................................................................................149 
 
6.2. Bias and precision of the estimated population pharmacokinetic parameter values 
obtained using Monolix, NONMEM, and Pmetrics for the incorrectly-specified 
models without covariates ......................................................................................154
 LIST OF FIGURES 
 
Figure               Page 
 
2.1. Chemical and molecular structures of the glycopeptide antibiotic vancomycin ......19 
 
2.2. Vancomycin concentration versus bacterial activity relationship ............................30 
 
2.3. Probability distribution for a hypothetical population of patients receiving 
vancomycin ...............................................................................................................33 
 
3.1. Diagnostic plots of the final model ...........................................................................80 
 
3.2. Visual predictive check for the final covariate model ..............................................83 
 
4.1. An external evaluation of the predictive performance of a previously published 
neonatal vancomycin population pharmacokinetic model ......................................102 
 
4.2. Assessment of the predictive performance of the neonatal vancomycin population 
pharmacokinetic model ...........................................................................................106 
 
4.3. The association between vancomycin trough concentrations and the extent of drug 
exposure, as measured by the 24-h area under the curve (AUC24) .........................107 
 
5.1. Zolpidem concentration versus time curves ...........................................................125 
 
5.2. Zolpidem final covariate model observed versus population-predicted concentrations 
and individual-predicted concentrations .................................................................127 
 
5.3. Zolpidem final covariate model conditional weighted residuals versus time and 
population-predicted concentrations and normalized prediction distribution errors as 
a function of time and population-predicted concentrations ...................................129 
 
5.4. Visual predictive check for observed zolpidem concentrations using the final 
covariate pharmacokinetic model ...........................................................................131 
 




6.2. Clearance and volume of distribution parameter estimates using correctly-specified 
covariate models .....................................................................................................147 
 
6.3. Precision of the population pharmacokinetic parameter estimates as a function of 
sample size and the number of concentrations obtained from each subject with 20% 
and 80% error, using correctly-specified covariate models ....................................151 
 
6.4. Clearance and volume of distribution parameter estimates using incorrectly-specified 
models without covariates.......................................................................................152 
 
6.5. Precision of the population pharmacokinetic parameter estimates as a function of 
sample size and the number of concentrations obtained from each subject with 20% 
and 80% error, using incorrectly-specified models without covariates ..................155 
  
 LIST OF ABBREVIATIONS 
 
AIC   Akaike information criterion 
APGAR Newborn scale based on appearance, pulse, grimace, activity, and 
respiration 
AUC   Area under the concentration versus time curve 
AUC24   24 hour area under the concentration versus time curve 
BMI   Body mass index 
BSV   Between subject variability 
CDC   United States Centers for Disease Control and Prevention 
CF   Cystic fibrosis 
CFU   Colony forming units 
CI   Confidence interval 
CL   Clearance 
CL/F   Apparent clearance 
Cmax   Maximum concentration 
Cmin   Minimum concentration 
Cr   Serum creatinine 
CRRT   Continuous renal replacement therapy 
CV   Coefficient of variation 
df   Degrees of freedom 
EM   Expectation maximization 
EMA   European Medicines Agency 
FDA   United States Food and Drug Administration 
GFR   Glomerular filtration rate 
IPRED   Individual predicted concentration 
IQR   Interquartile range 
Ka   Absorption rate 
MIC   Minimum inhibitory concentration 
MRSA   Methicillin-resistant Staphylococcus aureus 
MSSA   Methicillin-sensitive Staphylococcus aureus 
NICU   Neonatal intensive care unit 
NONMEM  Nonlinear mixed effects models 
NPAG   Nonparametric adaptive grid 
NPDE   Normalized prediction distribution error 
OFV   Objective function value 
PCH   Primary Children’s Hospital 
PMA   Postmenstrual age
PRED   Predicted concentration 
xiii 
Q   Intercompartmental clearance 
Q / F   Apparent intercompartmental clearance 
RSE   Relative standard error 
RUV   Residual unexplained variability 
SAEM   Stochastic approximation expectation maximization 
TBSAB  Cumulative percentage of the total burned body surface area 
V   Volume of distribution 
Vc / F   Apparent central volume of distribution 
Vd   Volume of distribution 
Vd / F   Apparent volume of distribution 
Vp / F   Apparent peripheral volume of distribution 
V1   Central volume of distribution 
V2   Peripheral volume of distribution 
WT   Body weight 
θ   Population pharmacokinetic parameter typical value 
ε   Residual variability 
η   Between subject variability 
σ   Residual variability standard deviation 
ω   Between subject variability standard deviation 
ω2   Between subject variability variance 
Ω   Variance-covariance matrices for η 
Σ   Variance-covariance matrices for ε 
 ACKNOWLEDGEMENTS 
 
 The work described in this dissertation was completed in the Division of Clinical 
Pharmacology in the Department of Pediatrics at the University of Utah under the 
supervision and mentorship of Dr. Catherine Sherwin.  Without her unending support, the 
work featured here would not have been possible. 
 Additionally, I owe a debt of gratitude to Dr. Christopher Reilly who has been my 
mentor and friend for nearly a decade. He encouraged me despite my utter ineptitude in the 
laboratory and has been an exemplary mentor in our more recent translational 
collaborations. 
 Lastly, I would like to thank Drs. Misty Smith, John Veranth, and Philip Moos, all 
of whom gave freely of their scientific and professional advice. It has been a pleasure to 
work with all of you—the members of my dissertation committee—over the last few years 




POPULATION PHARMACOKINETIC MODELING 
 
The Relationship between Clinical Trials and Population Pharmacokinetics 
 Confirmatory clinical trials aim to reject the null hypothesis that the treatment 
regimen under investigation has no effect.[1] By design, these trials study a limited number 
of doses in relatively homogeneous patient populations.[2] Unfortunately, these trials often 
only answer the very first question of interest to clinicians – is my patient likely to benefit 
from this therapy? If the answer is yes, then several other practical questions must also be 
asked, including: 
1) What is an appropriate initial dose for my patient? 
2) How soon will beneficial (and potentially harmful) effects start? 
3) How long will the beneficial (and potentially harmful) effects last? 
4) Will tolerance develop? 
5) What is the likelihood that the initial dose will need to be changed? 
6) What metrics should be used to determine if the dosing regimen needs to be 
changed? 




Sheiner raised these questions several years ago to illustrate the difference between 
confirmatory clinical trials and population pharmacokinetic studies.[2] Population 
pharmacokinetic analyses are well suited to the types of questions described above as they 
allow us to quantify and understand the variability in drug responses among a population 
of patients, which then makes it possible to develop personalized dosing regimens after 
establishing how an individual patient differs from the population at large.[3] 
 
Individual vs. Population Pharmacokinetics 
 Traditionally, pharmacokinetic studies have involved intensive serial blood 
sampling performed in a limited number of healthy, male, adult volunteers.[4-6] These 
studies allow the investigator to estimate the variability in plasma drug concentrations 
between individuals following the administration of a certain dose. In contrast, the 
population pharmacokinetic approach allows the investigator to characterize the 
pharmacokinetics of the drug of interest using fewer blood samples by treating all of the 
individuals in the study as a random sample from a larger population. From these data, it 
is then possible to estimate measures of central tendency for the pharmacokinetic 
parameters of the entire population, while simultaneously estimating within and between 
subject variability and quantifying the amount of residual, unexplained variability.[7] This 
improves the population mean and variance estimates and improves accuracy when 
selecting an initial dosing regimen or adjusting a dosing regimen in response to therapeutic 




History of Population Pharmacokinetics 
 Historically, pharmacokinetic analyses were conducted using a two-stage 
procedure in which each individual’s pharmacokinetic parameters were calculated using 
nonlinear regression methods. The parameters calculated for each individual were then 
averaged together to yield summary descriptive statistics for the population, including 
estimates of the mean pharmacokinetic parameter values and their variances. Similarly, 
other factors that influence the drug’s concentration-time profile were identified using 
classical statistical approaches (e.g., linear regression or covariance analysis). Although 
this approach has been shown to yield unbiased pharmacokinetic parameter estimates for 
the population mean, the variance and covariance are often overestimated.[8-11] 
 To better meet the needs of individual patients, Sheiner, Rosenberg, and Melmon 
developed a ‘conceptual scheme and associated statistical methodology designed to 
provide the basis for a clinically useful computer program to suggest optimal dosing 
regimens for a number of drugs’ in 1972.[12] This conceptual scheme and statistical 
methodology was purpose built to perform well in clinical scenarios with sparse amounts 
of data, where the traditional two-stage procedure failed. The principal factor that 
differentiates this approach is that it considers the cohort of patients being treated (the 
‘population’) as the unit of analysis, rather than the individual. Consequently, estimation 
of the pharmacokinetic parameters can be performed despite the use of sparse, unbalanced, 
or fragmented data, as compared with the two-stage procedure that required rigid, intensive 
sampling designs akin to those observed in prospective randomized controlled trials. 
Additionally, the nonlinear mixed effects modeling approach outlined by Sheiner, 
Rosenberg, and Melmon models the mean pharmacokinetic parameter values for the 
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population (derived from fixed effects terms) as well as the variability within the 
population (derived from random effects terms). For the remainder of this dissertation, this 
approach shall be interchangeably referred to as ‘population pharmacokinetic modeling’ 
and ‘nonlinear mixed effects modeling’. 
Building from their population pharmacokinetic conceptual framework, Sheiner 
and Beal developed the first version of NONMEM (nonlinear mixed effects modeling) in 
1980, which employed a first-order parameter estimation algorithm.[13, 14] 
Independently, in 1986, Mallet et al. developed the first nonparametric pharmacokinetic 
parameter estimation algorithm.[15] In 1990, Lindstrom and Bates developed the first-
order conditional estimation algorithm for nonlinear mixed effects models with repeated 
measures data.[16] Shortly thereafter, Schumitzky developed a nonparametric expectation 
maximization algorithm in 1991.[17] More recently, stochastic approximation expectation 
maximization algorithms were developed and simulations with interaction terms were 
conducted, which demonstrated their superiority over traditional first-order conditional 
estimation methods.[18-20] Additional details regarding the statistical methodologies 
employed in each of these iterative advancements in pharmacokinetic parameter estimation 
algorithms are described below. 
 
General Mathematical Formulation 
Population pharmacokinetic models involve the fitting of nonlinear mixed effects 
models to drug concentration data collected from multiple patients with the purpose of 
simultaneously estimating:  (1) the pharmacokinetic parameters for the typical individual 
in the population; (2) the variability within the population; and (3) the unexplained 
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variability that may result from measurement error or a poorly specified model.[13] The 
general mathematical formulation for a nonlinear mixed effects model is: 
𝑦𝑖𝑗 = 𝑓 (𝑡𝑖𝑗 , 𝑔(𝜃, 𝜂𝑖, 𝑥𝑖, 𝑧𝑖)) + ℎ(𝑡𝑖𝑗, 𝑔(𝜃, 𝜂𝑖 , 𝑥𝑖, 𝑧𝑖), 𝜀𝑖𝑗) (1.1) 
where 𝑓() is the function used to describe the structure of the model and ℎ() is the function 
used to describe the residual error model. 𝑡𝑖𝑗 represents the drug concentration measured 
for individual 𝑖 at time 𝑗. 𝑔() is a vector function that defines the 𝑖th individual’s 
pharmacokinetic parameters given the vector of typical value parameters 𝜃, the 𝑖th 
individual’s random effects 𝜂𝑖, the 𝑖
th individual’s vector of study design variables 𝑥𝑖 (e.g., 
the dosing regimen), and 𝑧𝑖, the 𝑖
th individual’s covariate vector (e.g., body weight, 
postmenstrual age, creatinine clearance, etc.). 
 It is unlikely that the pharmacokinetic parameters of the 𝑖th individual will perfectly 
match the typical pharmacokinetic parameter values for the population (𝜃); therefore, the 
individual pharmacokinetic parameters are said to deviate from 𝜃 by a vector of random 
effects terms of the same length as the number of pharmacokinetic parameters being 
estimated for the 𝑖th individual (𝜂𝑖), where 𝜂𝑖~𝑁(0, Ω). Here Ω is a covariance matrix that 
reflects the correlations between the individual pharmacokinetic parameters. The diagonal 
components of Ω reflect the between subject variability for each pharmacokinetic 
parameter. 
 The residual error model (𝜀𝑖𝑗) describes the difference between the individual 
predicted concentration and the measured drug concentration, which is assumed to follow 
a normal distribution of the form 𝜀𝑖𝑗~𝑁(0, Σ). 𝜀𝑖𝑗 is a vector of residual error terms and Σ 




Methodological Approaches Employed in Population Pharmacokinetic Analyses 
 To derive estimates of the population pharmacokinetic parameters maximum 
likelihood estimation methods are used. The maximum likelihood method specifies the 
probability density function for individual 𝑖 that optimizes the pharmacokinetic parameter 
estimates needed to maximize the likelihood of observing the vector of measured drug 
concentrations given the patient’s dosing record and covariate vectors. The joint 
probability distribution for 𝑦𝑖 and 𝜂𝑖 can be expressed as: 
𝑝(𝑦𝑖, 𝜂𝑖|𝜓) = 𝐿𝑖(𝜓|𝑦𝑖, 𝜂𝑖) = 𝑝(𝑦𝑖|𝜓, 𝜂𝑖) ∗ 𝑝(𝜂𝑖|𝜓) (1.2) 
in which 𝐿𝑖 is the 𝑖
th individual’s likelihood given 𝑦𝑖 and 𝜂𝑖. 𝜓 is the vector of the typical 
parameter values (𝜃) and the variance-covariance matrices (Ω and Σ). 𝑝(𝑦𝑖|𝜓, 𝜂𝑖) is the 
conditional probability density of the measured drug concentrations (𝑦𝑖) given 𝜓 and 𝜂𝑖. 
Lastly, 𝑝(𝜂𝑖|𝜓) is the conditional probability density of 𝜂𝑖 given 𝜓; however, since 𝜂𝑖 
cannot be measured experimentally the marginal distribution of the measured drug 
concentrations (𝑦𝑖) is reformulated to yield the following likelihood function: 
𝐿(𝑦|𝜓) = ∫ 𝑝(𝑦𝑖|𝜂𝑖, 𝜓) ∙ 𝑝(𝜂𝑖, 𝜓) 𝑑𝜂𝑖 (1.3) 
where 𝑝(𝑦𝑖|𝜂𝑖 , 𝜓) is the conditional probability of the measured drug concentrations (𝑦𝑖) 
given the vector of random effects (𝜂𝑖) and 𝜓. 𝑝(𝜂𝑖, 𝜓) denotes the joint population 
parameter density of the individual random effects. 
 For nonlinear functions, the likelihood cannot be maximized with a closed form 
solution. Therefore, several specialized software programs have been developed to 
approximate the maximum likelihood estimation. The most commonly used is the 
nonlinear mixed effects modeling program NONMEM (ICON Development Solutions, 
Ellicott Bay, MD, United States), which approximates the integrand and yields a closed 
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form expression for 𝐿(𝑦|𝜓) that is computationally tractable.[21] Initially, NONMEM 
utilized a first-order algorithm, which is known to result in biased parameter estimates with 
high between subject variability.[22] More recently, NONMEM has adopted a first-order 
conditional estimation algorithm in which the individual random effects estimates from the 
current iteration of the model are conditionally estimated from the random effects estimates 
obtained from the previous iteration of the linearized model.[23] 
An alternative pharmacokinetic parameter estimation algorithm is employed in the 
software program Monolix (Lixoft, Orsay, France), which uses expectation maximization 
(EM) methods that integrate the posterior density by performing Monte Carlo sampling 
over all possible individual parameters during the expectation step, which is then followed 
by a single iteration maximization step that moves the pharmacokinetic parameter value 
closer toward the maximum likelihood.[24] Delyon et al. demonstrated that the EM 
algorithm converges under very general conditions and Kuhn and Lavielle further 
established that the coupling of the EM algorithm with the Markov Chain Monte Carlo 
procedure rapidly converses toward the maximum likelihood estimate.[25, 26] 
Pmetrics is another commonly used population pharmacokinetic modeling program 
that makes no assumptions regarding the distribution of the density function.[17] Pmetrics 
uses a nonparametric adaptive grid algorithm that performs no formal numerical 
optimization; rather it quasi-Monte Carlo methods to generate a grid of Faure points that 
can be rapidly tested to assess whether they improve the likelihood beyond the grid 
consisting of points derived from the model’s initial estimates.[27] More specifically, this 
deterministic set of Faure points is used to approximate the integration featured in Equation 
1.3.[27] This process is iteratively repeated to yield a final, discrete nonparametric 
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distribution of pharmacokinetic parameter estimates.[27] This algorithm has the advantage 
of appropriately identifying sub-populations with different pharmacokinetic profiles (e.g., 
varying hepatic formation clearances of CYP3A-metabolized drugs due to genetic 
polymorphisms that affect the level of CYP3A expression).[28] 
As noted above, several specialized population pharmacokinetic modeling 
programs have emerged over the last 30 years that employ different pharmacokinetic 
parameter estimation algorithms, which have the potential to lead to dramatically different 
results.[21, 24] For this reason, benchmarks are needed to experimentally assess the 
strengths and weaknesses of current population pharmacokinetic modeling programs. The 
accuracy and precision of these estimates may impact clinical decisions and lead to 
alterations in medical management, such that the selection of a pharmacokinetic parameter 
estimation method with lower bias and higher precision is desirable.  
 
Applications of Population Pharmacokinetics 
 The drug development process involves several iterative stages in which 
compounds are evaluated to confirm their safety and efficacy prior to regulatory approval, 
marketing, and widespread use.[29] Population pharmacokinetic modeling is used to 
increase our understanding of the quantitative relationships between drug dosing regimens, 
patient characteristics, and drug pharmacokinetics. Today, the use of population 
pharmacokinetic modeling is actively encouraged by the United States Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA).[29, 30] Despite the 
widespread acceptance of population pharmacokinetic methods in the drug approval 
process, relatively few population pharmacokinetics studies have been conducted among 
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children. Rectifying this scarcity of pediatric-specific population pharmacokinetic data has 
the potential to:  (1) result in optimized dosing regimens that improve therapeutic 
effectiveness across the pediatric age spectrum from neonates to adolescents; (2) reduce 




 Deriving the ‘optimal’ individualized dose that is neither ineffective nor toxic is the 
ultimate goal of many physicians, pharmacologists, regulatory agencies, and 
pharmaceutical companies.[32] Achieving this goal is challenging for many drugs due to 
pharmacokinetic variability within and between patients. For drugs with narrow 
therapeutic windows (a small margin separates sub-therapeutic from toxic concentrations), 
it is necessary to conduct population pharmacokinetic studies to determine whether 
predictable factors (covariates) can be identified that influence the extent and peak of drug 
exposure.[33] If substantial variability remains after such investigations and a target 
concentration range has been established, then it may be prudent to measure drug 
concentrations in each patient (a practice known as therapeutic drug monitoring).[34, 35] 
Drug concentration measurements obtained from therapeutic drug monitoring can then be 






Statement of Objectives 
 The objective of this dissertation is to demonstrate the clinical utility of population 
pharmacokinetic models and to assess the predictive performance of several population 
pharmacokinetic modeling programs that are commonly used in evaluating drug 
concentration time profiles and the response to therapy. 
 The specific aims are as follows: 
1) Define the population pharmacokinetics of two drugs belonging to 
different drug classes in a selection of rarely-studied pediatric patient 
populations. These analyses include an evaluation of the population 
pharmacokinetics of: 
 Vancomycin among children with invasive methicillin-
resistant Staphylococcus aureus (MRSA) infections; and 
 Zolpidem among children with severe burn injuries. 
2) Assess the performance of several commonly used population 
pharmacokinetic software programs in establishing precise and 
unbiased pharmacokinetic parameter estimates with varying:  amounts 
of error / noise, sample sizes, and numbers of samples from each 
patient. 
The foundation for the first specific aim is outlined in Chapter 2. Chapters 3 and 4 
discuss two clinical applications of vancomycin population pharmacokinetic models 
among children with cystic fibrosis and neonates with invasive bacterial infections, 
respectively. Chapter 5 describes a population pharmacokinetic study involving the 
sedative agent zolpidem, which was administered in an effort to restore normal sleep 
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architecture among a cohort of severely burned children. Chapter 6 describes a simulation-
based approach to benchmarking population pharmacokinetic software programs and is 
under preparation for submission.  Publications that have stemmed directly from this work 
include: 
 Stockmann C, Roberts JK, Yu T, et al. Vancomycin pharmacokinetic models: 
informing the clinical management of drug-resistant bacterial infections. Expert 
Review of Anti-infective Therapy 2014; 12(11): 1371-88. 
 Stockmann C, Sherwin CM, Zobell JT, et al. Population pharmacokinetics of 
intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy 
2013; 33(12): 1288-96. 
 Stockmann C, Hersh AL, Roberts JK, et al. Predictive performance of a 
vancomycin population pharmacokinetic model in neonates. Infectious 
Diseases and Therapy 2015; 4(2): 187-98. 
 Stockmann C, Sherwin CM, Buterbaugh W, et al. Preliminary assessment of 
zolpidem pharmacokinetics in pediatric burn patients. Therapeutic Drug 
Monitoring 2014; 36(3): 295-301. 
 Stockmann C, Gottschlich M, Healy D, et al. Relationship between zolpidem 
concentrations and sleep parameters in pediatric burn patients. Journal of Burn 
Care and Research 2014; 36(1):137-44. 
During the course of this dissertation, several fruitful collaborations have also led 
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VANCOMYCIN PHARMACOKINETIC MODELS: INFORMING 




 This review aims to critically evaluate the pharmacokinetic literature describing the 
use of vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) 
infections. Guidelines recommend that trough concentrations be used to guide vancomycin 
dosing for the treatment of MRSA infections; however, numerous in vitro, animal model, 
and clinical studies have demonstrated that the therapeutic effectiveness of vancomycin is 
best described by the area under the concentration versus time curve (AUC) divided by the 
minimum inhibitory concentration (MIC) of the infecting organism (AUC/MIC). Among 
patients with lower respiratory tract infections, an AUC/MIC≥400 was associated with a 
superior clinical and bacteriological response. Similarly, patients with MRSA bacteremia 
who achieved an Etest AUC/MIC≥320 within 48 hours were 50% less likely to experience 




children, the elderly, patients with osteomyelitis, etc.) pharmacokinetic/pharmacodynamic 




 Vancomycin was first approved for use by the United States Food and Drug 
Administration (FDA) in 1958.[1] Despite more than 50 years of experience with this 
antibiotic, uncertainty remains regarding the most appropriate vancomycin dosing 
strategy.[2] This is primarily attributable to its variable pharmacokinetic profile, the 
emergence of vancomycin resistance, and its toxic effects.[3] Currently, intravenous 
vancomycin is reserved nearly exclusively for the treatment of methicillin-resistant 
Staphylococcus aureus (MRSA) infections, which until the late 1970s and early 1980s were 
extremely rare and confined to a few large hospitals.[4] More recently, other factors, such 
as the controversial ‘MIC creep’ phenomenon and a heightened awareness of the potential 
for sub-therapeutic dosing have further complicated vancomycin dosing. At the level of an 
individual patient, high between subject variability complicates efforts to develop 
simplified or standardized vancomycin dosing regimens.[5] Despite these challenges, 
pharmacokinetic and pharmacodynamic modeling techniques may be used to inform 
vancomycin dosing, even for adult populations, for which large amounts of data exist.[2] 
 Over the last 10 years, vancomycin dosing regimens have shifted toward larger, 
more frequent doses.[6] This has likely occurred in response to in vitro studies, which 
demonstrated that low vancomycin concentrations exert a selective pressure that drives the 
emergence of more resistant S. aureus isolates.[7] To prevent such occurrences, 
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professional society guidelines have increased vancomycin exposure targets in an effort to 
more rapidly achieve and maintain therapeutic concentrations.[8] Consequently, many 
patients who receive vancomycin today are being maintained at concentrations that are 
closer to levels associated with nephrotoxicity than ever before, which makes therapeutic 
drug monitoring imperative.[9] Simultaneously, there has been an increase in the incidence 
of hospital- and community-associated MRSA.[10] In 2003, nearly 60% of S. aureus 
isolates obtained from patients in the intensive care unit were methicillin-resistant.[11, 12] 
More recently, the US Centers for Disease Control and Prevention (CDC) estimated that 
the incidence of MRSA infections declined 31% from 2007 to 2012.[13] Although the 
reasons for this decline are unclear, the continued widespread use of vancomycin in the 
context of fewer invasive MRSA infections poses substantial risks and must be evaluated 
in light of the potential for promoting vancomycin resistance. 
 The safe and effective administration of vancomycin at the level of the individual 
patient, especially in light of current practice patterns, may require more sophisticated 
techniques than merely dosing by total body weight and estimated renal function.[14] 
Population pharmacokinetic models, which leverage data from a population of patients to 
derive an optimal population-specific dosing strategy, are one such example.[15] When 
applied to direct patient care, the purpose of population pharmacokinetic modeling is to 
provide quantitative and semi-quantitative guidelines for dose optimization. Unlike 
traditional pharmacokinetic evaluations, the population pharmacokinetic approach is 
unique in that it:  (1) derives pharmacokinetic parameter estimates that are representative 
of the population being treated; (2) recognizes sources of variability (e.g., between subject, 
intra-subject, and inter-occasion variability); (3) identifies factors that influence the 
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pharmacokinetic behavior of the drug; and (4) quantitatively expresses the magnitude of 
the unexplained variability within the patient population being treated.[15] For patients 
requiring antibiotic therapy for the treatment of drug-resistant bacterial infections it is 
critical to quickly establish an effective and safe dosing regimen. Consequently, the 
purpose of this review is to critically evaluate the vancomycin pharmacokinetic literature 
with respect to its use in the treatment of MRSA infections. A secondary objective is to 
identify special patient populations who may require alternative vancomycin dosing 
regimens as a consequence of their demographic factors, physiologic status, or co-morbid 
conditions. The patient populations investigated in this review include:  neonates and 
infants, children and adolescents, the elderly, obese patients, cancer patients, patients 
requiring continuous renal replacement therapy, patients with cystic fibrosis, and the 
critically ill. Emphasis will be placed on the integration of vancomycin population 
pharmacokinetic models into clinical care and the role that vancomycin therapeutic drug 




 The chemical structure of vancomycin is presented in Figure 2.1. 
 
Absorption 
 Vancomycin is not well absorbed through the gastrointestinal tract and therefore 
achieves high colonic concentrations, which have been reported to range from 500-1000 




Figure 2.1. Chemical (A) and molecular (B) structures of the glycopeptide antibiotic 
vancomycin.   
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profile, vancomycin is recommended for the treatment of Clostridium difficile 
infections.[17] However, it must be noted that patients with bowel inflammation can have 
increased absorption following oral vancomycin administration.[18] Moreover, patients 
with severe renal disease and inflammatory bowel disease have the potential to reach toxic 
serum concentrations.[18, 19] Other modes of administration, such as intraperitoneal, 
intraventricular, and intrathecal dosing, have been rarely reported.  Bunk et al. compared a 
single 10 mg/kg dose of vancomycin administered intravenously to a 10 mg/kg dose given 
intraperitoneally and noted that 65% of the intraperitoneal dose was absorbed, which 
yielded a peak plasma concentration of 6.3 mcg/mL.[20] They suggested that therapeutic 
plasma concentrations in excess of 10 mcg/mL could be reached with an intraperitoneal 
dose of 30 mg/kg followed by 1-5 mg/kg in each peritoneal exchange for patients in chronic 
renal failure. Intraventricular and intrathecal dosing have been described in several case 
reports, all of which reported high cerebrospinal fluid (CSF) concentrations without 
evidence of high serum concentrations.[21, 22] For the treatment of MRSA infections, 
vancomycin is commonly administered intravenously due to its poor oral bioavailability 
and extreme pain associated with intramuscular administration.[23] Therefore, the 
remainder of this review will focus on the intravenous use of vancomycin, which is 
delivered as a slow intravenous infusion with a standard infusion time of approximately 1 
hour for a 1 g dose to avoid red man syndrome.[24-26] 
 
Distribution 
 Vancomycin time-versus-concentration profiles have been reported as mono-, bi-, 
or triphasic, though the majority of the literature suggests a biphasic process after 
intravenous administration.[4, 27-30] The α-distribution phase ranges from 0.5-1 hr and 
21 
 
the β-elimination half-life is between 6-12 hrs in adults with normal renal function, which 
demonstrates its high between subject variability.[4, 28-31] After a single administration 
of the recommended dose of 15 mg/kg, peak serum concentrations at 2 hrs after infusion 
reach approximately 25 mcg/mL.[32, 33] Vancomycin is highly hydrophilic, with a volume 
of distribution at steady state comparable to that of total body water.[34, 35] The volume 
of distribution has been reported to range from 0.39-2.04 L/kg at steady state and is 
influenced by age, gender, and body weight.[4, 28-31, 36] The volume of the central 
compartment is approximately 10% of the volume of distribution, which is similar to the 
total volume of blood.[31] Protein binding in the serum is moderate, with most reports 
ranging from 50-55%.[37, 38] Due to its large volume of distribution, vancomycin readily 
crosses into ascitic, pericardial, synovial, and pleural fluids.[39] In addition, concentrations 
in abscess fluid are similar to those in serum.[40] Very low concentrations of vancomycin 
cross the blood brain barrier (0-0.18 CSF to serum ratios), unless the meninges are 
inflamed, which can then result in CSF to serum ratios of 0.36-0.48.[41, 42]  
Concentrations in lung tissue range from 5-50% of serum concentrations and have an 
overall blood to epithelial lining fluid ratio of 6:1 in critically ill patients.[43-46] 
Vancomycin concentrations in the bone are approximately 10% of serum concentrations, 
though this increases to 20-30% in infected bone.[47] An exploratory analysis of the 
pharmacokinetics and tissue penetration of vancomycin administered via continuous 
infusion as prophylaxis for vascular surgery found that vancomycin concentrations in the 
arterial wall were approximately 50% of those found in the serum; however, penetration 





 Early pharmacokinetic studies indicated that vancomycin is not efficiently 
metabolized.[32, 49] However, more recent studies have suggested that hepatic clearance 
may occur to a small degree, although these reports failed to find evidence of a prolonged 
vancomycin half-life among patients with impaired hepatic function.[29, 30] In addition, 




 Up to 90% of the vancomycin dose is excreted unchanged within 24 hrs.[25] Renal 
excretion occurs primarily through glomerular filtration.[31] Nielsen et al. reported a 
vancomycin clearance to creatinine clearance ratio of 0.53 ± 0.11.[51] Similarly, Krogstad 
et al. reported a mean vancomycin clearance to creatinine clearance ratio of 0.68 ± 
0.07.[31] These discrepancies may be suggestive of renal tubular reabsorption; however, 
no definitive reports have documented renal tubular reabsorption in humans and this 
discrepancy may be explained by moderate serum protein binding.[39] In adult population 
pharmacokinetic models, vancomycin clearance has been found to be highly correlated 
with creatinine clearance, weight, and age.[52-58] If creatinine clearance is not measured 
directly, the Cockroft-Gault equation may be used, which includes body weight, sex, age, 





Considerations for Pharmacokinetic Modeling 
 Many vancomycin population pharmacokinetic models have been published for 
adults in the last 20 years.  In this section of the review, we will focus on studies that 
evaluated adults with serious drug-resistant bacterial infections. In coming sections, studies 
evaluating patients with renal impairment and other pathophysiologic process and co-
morbidities will be discussed at length. 
Seven seminal adult vancomycin pharmacokinetic modeling studies are presented 
in Table 2.1. The age ranges across these studies varied from 17-95 years.[52-54, 56-58] 
With regard to the development of the vancomycin structural model, several used one-
compartment models and several others used two-compartment models. Vancomycin is 
well-known to feature a biphasic distribution and elimination phase, which is revealing as 
studies that involved intensive sampling often fit a two-compartment model; whereas 
sparse sampling schemes often could only fit a one-compartment model. Between subject 
variability was modeled using an exponential,[53, 55, 57, 58] a combined,[52] a 
proportional,[54] and an additive error model.[56] The between subject variability ranged 
from 19.8-38.5% and 18.2-36.4% for clearance and volume of distribution, respectively. 
Residual unexplained variability was modeled as an additive,[53, 56] combined,[52, 54, 
55] and an exponential error model.[57, 58] Residual variability for the exponential and 
additive models ranged from 12.7-24.9% and 1.6-18.5%, respectively. The estimates for 
clearance ranged from 0.031-0.086 L/hr/kg in adults.[52-58] Estimates reported for the 
volume of distribution from the central compartment were quite variable, ranging from 
0.39-2.04 L/kg.[57, 60] The majority of the population pharmacokinetic studies reported 
an effect of creatinine clearance or the rate of glomerular filtration on clearance.[2, 52]  In   
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Table 2.1. A comparison of adult vancomycin population pharmacokinetic studies. 
Study (Year)   Ref. 
Revilla et al. 
(2010) 
Patient population Intensive care unit patients 53 
 Number of patients studied 191  
 
Age, years (median 
[range], 
mean ± standard deviation) 
61.1 ± 16.3 [18-85]  
 Number of compartments One  
 
Final model (central 
compartment) 
CL = θ1 x CLCR + Ageθ2 
V = θ3 x θ4A, where A = 0 if 
SCr ≤1 mg/dL and A = 1 if SCr 
>1 mg/dL 
 
 Clearance 0.67 mL/min/kg  
 Volume of distribution 0.82 L/kg  
 
Between subject variability 
model 
Exponential  
 Residual variability model Additive  
 Validation External  
Thomson et al. 
(2009) 
Patient population Adults who received 
vancomycin 
82 
 Number of patients studied 398  
 
Age, years (median 
[range], 
mean ± standard deviation) 
66 [16-97]  
 Number of compartments Two  
 
Final model CL = θ1 x CLCR 
V1 = θ3 x Total body weight 
Q  = θ4 
V2 = θ5 x Total body weight 
 
 
Clearance CL = 2.99 L/hr 
Q  = 2.28 L/hr 
 
 
Volume of distribution V1 = 0.675 L/kg 
V2 = 0.732 L/kg 
 
 
Between subject variability 
model 
Exponential  
 Residual variability model Combined  
 Validation External  
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Table 2.1. Continued. 
Staatz et al. 
(2006) 
Patient population Cardiothoracic surgery wound 
infections 
55 
 Number of patients studied 102  
 Age, years (median 
[range], 
mean ± standard deviation) 
66 [17-81]  
 Number of compartments One  
 Final model (central 
compartment) 
CL = θ1 x (1 + θ2 x (CLCR – 
CLCR, median)) 
V = θ3 
 
 Clearance 2.97 L/hr  
 Volume of distribution 1.24 L/kg  
 Between subject variability 
model 
Exponential  
 Residual variability model Combined  
 Validation External  
Tanaka et al. 
(2010) 
Patient population MRSA infections 56 
 Number of patients studied 164  
 Age, years (median 
[range], 
mean ± standard deviation) 
74 [17-94]  
 Number of compartments One  
 Final model (central 
compartment) 
CL = θ1 x GFR 
V = θ2 
 
 Clearance 0.88 L/hr  
 Volume of distribution 0.86 L/kg  
 Between subject variability 
model 
Additive  
 Residual variability model Additive  









Table 2.1. Continued. 
 Number of patients studied 50  
 Age, years (median 
[range], 
mean ± standard deviation) 
60 [18-81]  
 Number of compartments Two  
 Final model (central 
compartment) 
CL = θ1 + θ2 x CLCR 
V = θ3 x WT 
 
 Clearance 0.03 L/hr  
 Volume of distribution 0.41 L/kg  
 Between subject variability 
model 
Combined  
 Residual variability model Combined  
 Validation Internal  
Sanchez et al.  
(2010) 
Patient population Adults who received 
vancomycin 
54 
 Number of patients studied 141  
 Age, years (median 
[range], 
mean ± standard deviation) 
55 ± 14.6  
 Number of compartments Two  
 Final model (central 
compartment) 
CL = θ1 + θ2 x CLCR 
V = θ3 x WT 
 
 Clearance 0.16 L/hr  
 Volume of distribution 0.28 L  
 Between subject variability 
model 
Proportional  
 Residual variability model Combined  
 Validation External  
Yamamoto et 
al. (2009) 
Patient population Gram-positive infections 57 
 Number of patients studied 100  
 Age, years (median 
[range], 
mean ± standard deviation) 





Table 2.1. Continued. 
 Number of compartments Two  
 Final model (central 
compartment) 
CL = θ1 
V = θ4 x WT 
 
 Clearance 3.83 L/hr  
 Volume of distribution 0.48 L  
 Between subject variability 
model 
Exponential  
 Residual variability model Exponential  
 Validation Internal  
Yasuhara et al. 
(1998) 
Patient population MRSA infections 58 
 Number of patients studied 190  
 Age, years (median 
[range], 
mean ± standard deviation) 
64.3 ± 13.8 [19.3-89.6]  
 Number of compartments Two  
 Final model (central 
compartment) 
CL = θ1 
V = θ3 
 
 Clearance 3.51 L/hr  
 Volume of distribution 60.7 L (steady state)  
 Between subject variability 
model 
Exponential  
 Residual variability model Exponential  




addition, weight and age were the most common covariates that affected the volume of 
distribution. No categorical covariates had a significant effect on clearance or the volume 
of distribution. Model evaluations were evenly distributed between internal (bootstrap or 
visual predictive check)[52, 56, 57] and external validation procedures.[53-55] 
 
Pharmacodynamic Profile 
 The vast majority of vancomycin pharmacodynamic studies have been conducted 
in vitro. However, in the last decade a few in vivo pharmacodynamic studies have been 
conducted, many of which will be discussed at length in this section of the review. 
 
Exposure-Response Profiles 
When evaluating the exposure-response profile of an antibiotic it is necessary to 
consider the magnitude of the drug exposure and its potency against a specific bacterial 
pathogen.[61] In developing exposure-response profiles, both of these may be 
quantitatively expressed as a ratio of the drug exposure (e.g., maximum concentration or 
the area under the concentration time curve [AUC]) and its potency (expressed as the 
minimum inhibitory concentration [MIC]).[61] As a consequence of the wide range of 
MICs among different pathogenic microorganisms, these pharmacokinetic / 
pharmacodynamic ratios have a broader range when compared to those that include a single 





Pharmacokinetic / Pharmacodynamic Indices 
 In vivo antibacterial activity may be predicted from two factors:  (1) the antibiotic 
concentration at the effect site and (2) the duration of time that the pathogen is exposed to 
the antibiotic.[62] Consequently, numerous in vitro and animal studies have been 
conducted to evaluate which pharmacokinetic / pharmacodynamic index best predicts 
vancomycin antibacterial activity.[63-65] These studies demonstrated that the relationship 
between vancomycin concentrations and bacterial killing is best described by the AUC 
divided by the MIC of the infecting pathogen (AUC / MIC) (Figure 2.2).[64, 66] In murine 
infection models, the vancomycin AUC / MIC was the best predictor of bacterial killing 
against MSSA, MRSA, and vancomycin intermediate S. aureus (VISA).[67, 68] 
 
Antibiotic Susceptibility Testing 
 Antibiotic susceptibility testing results range from quantitative (e.g., actual MIC 
values) to qualitative (e.g., susceptible, intermediate, resistant).[62] For the latter, it is 
critical to determine whether the MIC breakpoints are chosen to detect drug resistance or 
to predict the antibacterial activity of a drug for a patient receiving a typical dose of the 
antibiotic.[69] These are two fundamentally different questions that are often not clarified 
when breakpoint MICs are selected. For the purpose of conducting pharmacokinetic / 
pharmacodynamic analyses, it is preferable to use actual MIC values and establish MIC 
breakpoints (if needed) based upon the intended goals of the analysis. 
In seeking to predict whether a given vancomycin regimen is likely to be effective 
for an individual patient there are several factors that must be considered, including the 


























































































































































































































































































































practice. Reliable predictions are challenging to develop as MIC-based vancomycin 
susceptibility tests are based primarily on the in vitro determination of the inhibition of 
growth for standardized low inocula (105-106), exponential-phase staphylococci.[3] As 
such, the MIC does not take into account the effects of vancomycin on higher inocula, such 
as those seen in the setting of critical illness.[70-73] Additionally, the effects of biofilm 
formation and stationary-phase growth are not taken into account with current vancomycin 
susceptibility testing methods.[73] Consequently, others have suggested that alternative 
pharmacokinetic / pharmacodynamic indices, such as the time above a multiple of the MIC, 
the time above the stationary-phase maximum bactericidal concentration, or the time above 
an inoculum-corrected MIC may be more accurate predictors of vancomycin efficacy in 
clinical practice.[3] However, these targets have not been evaluated in clinical trials yet 
and the AUC / MIC ratio remains the most widely accepted vancomycin pharmacokinetic 
/ pharmacodynamic index. 
 
Considerations for Pharmacodynamic Modeling 
 To optimize antibacterial activity and improve patient safety, vancomycin 
therapeutic drug monitoring is recommended for patients with invasive MRSA infections 
by the Infectious Diseases Society of America.[74] This practice involves the collection of 
serum samples that are assayed to determine the concentration of vancomycin at specified 
time-points.[75] These data may then be used in combination with MIC data to derive 
optimal patient-specific vancomycin dosing regimens.[75] Although this approach 
represents a major advance in the field of personalized medicine several limitations hinder 
its widespread adoption, including:  the requirement for collecting multiple blood samples, 
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rapid determination of the MIC, and the need for sophisticated modeling software to 
integrate the pharmacokinetic / pharmacodynamic data and provide individualized dosing 
recommendations.[62] 
Population pharmacokinetic / pharmacodynamic modeling leverages historical data 
describing the variability in vancomycin pharmacokinetics and the range of bacterial MICs 
encountered in clinical practice to derive probability density functions for the likelihood of 
achieving specific pharmacokinetic / pharmacodynamic targets (Figure 2.3).[76] Monte 
Carlo simulations are commonly used for this purpose.[77] In the case of invasive MRSA 
infections, a local hospital may establish its range of MICs using data from previous years 
and develop a probability density function that describes the likelihood that an MRSA 
isolate will have an MIC <1, 1-2, or ≥2 mcg/mL. Additionally, historical data may be used 
to establish the likelihood that a patient treated with a typical dose of vancomycin will have 
an AUC <200, 200-400, or >400 mcg*hr/mL. These distributions may then be used as 
inputs to develop a large number of computer simulations exploring possible AUC / MIC 
ratios. For each simulation, a single random AUC value is chosen along with a random 
MIC value, in accordance with their respective probabilities. As the simulation proceeds, 
large numbers of AUC and MIC pairs are developed allowing one to summarize the 
resulting AUC / MIC ratios as a function of their probability distribution. It is then possible 






Figure 2.3. Probability distribution for a hypothetical population of patients receiving 
vancomycin. In this example, (A) a compartmental model is used to describe vancomycin 
pharmacokinetics, which allows the AUC to be determined by dividing the dose by the 
estimated clearance rate. (B) The distribution of methicillin-resistant Staphylococcus 
aureus MIC values is used to define the range of MICs observed in the hypothetical 
population of patients. (C) The AUC / MIC ratio may be determined using Monte Carlo 







 Vancomycin dosing guidelines recommend that pharmacokinetic / 
pharmacodynamic targets be used to guide the clinical management of MRSA 
infections.[75] These guidelines rely heavily upon a study by Moise-Broder et al. that 
evaluated 108 patients hospitalized with S. aureus lower respiratory tract infections who 
required vancomycin treatment.[78] In this study, the authors found that the clinical and 
bacteriological response was superior among patients with an AUC / MIC ≥400. Moreover, 
an AUC / MIC ≥400 was associated with a decreased time to bacterial eradication and a 
decrease in the time to improved pneumonia scores. In contrast, no relationship was defined 
between the time above the MIC and the clinical response to therapy. It should be noted 
that MICs were determined using the broth microdilution method in this study, which has 
been recently shown to result in higher AUC / MIC targets when compared to the Etest 
method.[2, 78] Additionally, the vancomycin AUC was not calculated from measured 
vancomycin concentrations but was instead predicted from renal function (creatinine 
clearance). 
Following the publication of consensus recommendations from several leading 
professional societies that endorsed a vancomycin AUC / MIC ≥400 target for all serious 
MRSA infections, Holmes et al. evaluated this target among 182 patients with S. aureus 
bacteremia (77% MRSA).[79] The authors found that a broth microdilution AUC / MIC 
≥400 was not associated with lower 30-day all-cause or attributable mortality from S. 
aureus bacteremia. However, using classification and regression tree methods, it was found 
that an AUC / MIC >373 within the first 96 hours of therapy was associated with a 
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reduction in mortality, following adjustment for potential confounders. This effect 
persisted in subgroup analyses limited comparing cases of MRSA versus MSSA and low 
versus high MICs (defined as an Etest MIC value >1.5 mcg/mL). 
Several recent studies have suggested that the AUC / MIC ≥400 target may not be 
universally applicable for all MRSA-associated clinical syndromes.[80, 81] Brown et al. 
found that an AUC / MIC <211 was associated with increased mortality among patients 
with MRSA bacteremia and infective endocarditis.[80] Additionally, Gawronski et al. 
investigated the association between AUC / MIC ratios and the time to microbiological 
clearance in patients with MRSA bacteremia and osteomyelitis.[81] The authors used the 
classification and regression tree method to determine that an AUC / MIC >293 yielded 
the greatest difference in the time to microbiological clearance. For patients with an AUC 
/ MIC >293 the mean time to clearance was two days shorter (4 vs. 6 days of bacteremia). 
Additional prospective clinical trials are warranted to confirm these findings. 
 
Trough Concentration Targets 
Historically, vancomycin trough concentrations have been used as a marker of 
vancomycin exposure.[74] Current clinical practice guidelines recommend that a minimum 
trough concentration of 10 mcg/mL is recommended to achieve antibacterial activity and 
to avoid promoting bacterial resistance.[74] For invasive MRSA infections, a therapeutic 
trough concentration target of 15-20 mcg/mL is recommended, which was predictive of an 
AUC / MIC >400 among adults with S. aureus lower respiratory tract infections.[78] 
However, Gawronski et al. found that trough concentrations did not correlate with AUC / 
MIC ratios among patients with MRSA bacteremia and osteomyelitis.[81] Consequently, 
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the authors recommended that total drug exposure be estimated by measuring the AUC / 
MIC for each patient to ensure optimal dosing. 
 
Empiric and Definitive Dosing Regimens 
 Vancomycin is frequently prescribed empirically for the treatment of presumed 
MRSA infections. Conventional dosages (1 g every 12 hrs or 15-20 mg/kg actual body 
weight every 8-12 hrs) are recommended for adult patients with normal renal function.[75] 
However, to reliably achieve a vancomycin trough concentration of 10-15 mcg/mL or an 
AUC / MIC > 400, Thomson et al. demonstrated that alternative dosing strategies may be 
needed.[82] The authors developed a population pharmacokinetic model using data from 
398 patients with a median age of 66 years (range 16-97) who received vancomycin from 
1991-2004 and subsequently evaluated its performance using data from 100 patients 
(median age 71 years [range 22-91]) treated with vancomycin from 2004-2007. Using 
conventional dosing guidelines 19% of patients achieved a trough within 10-15 mcg/mL. 
The authors then used the population pharmacokinetic parameter estimates derived from 
their model to predict vancomycin trough concentrations in a simulated dataset of 110 
patients with varying weights (40-120 kg) and creatinine clearance (15-125 mL/min). 
Revised dosing recommendations were then generated by examining the likelihood of 
achieving a target trough concentration of 10-15 mcg/mL at doses with fixed increments 
of 250 mg administered at intervals of 12, 24, and 48 hours. This process was repeated 
until the authors established a series of dosing recommendations that resulted in 55% of 
patients in the simulated dataset achieving the target trough concentration of 10-15 
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mcg/mL. Using these dosing recommendations, 87% of the simulated patients were 
predicted to achieve an AUC / MIC >400. 
For MRSA isolates with an MIC equal to 1 mcg/mL, definitive vancomycin doses 
should be maintained at a higher level (60 mg/kg/day) to achieve trough concentrations of 
15-20 mcg/mL.[8] Despite the use of larger doses, however, Patel and colleagues used 
Monte Carlo simulation techniques and found that the probability of achieving an AUC / 
MIC >400 was only 57% with an aggressive dosing regimen of 2 g every 12 hrs when the 
MIC was equal to 2 mcg/mL; in contrast to approximately 100% target attainment when 
MICs were ≤1 mcg/mL.[14] A similar trend was noticed by Gawronski et al., in which 
only 9% of patients were able to reach an AUC / MIC >400 with MICs >1 mcg/mL.[81] 
Based on these findings, alternative antibiotics (e.g., linezolid) should be considered for 
MRSA isolates with MICs >1 mcg/mL. 
 
Continuous Infusion 
 Continuous infusion of vancomycin features several practical advantages, 
including lower costs, decreased pharmacokinetic variability, and increased ease of 
monitoring when compared to intermittent infusion.[83, 84] A recent meta-analysis 
evaluated one randomized controlled trial and five observational studies and found that 
continuous infusion was associated with a lower risk of nephrotoxicity and no difference 
in mortality.[85] This finding is in agreement with a study by Hutschala et al., which found 
that critically ill patients undergoing cardiac surgery had a lower incidence of acute renal 
failure requiring venovenous hemofiltration after vancomycin was administered via 
continuous infusion as compared to intermittent infusion.[86] Roberts et al. evaluated the 
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population pharmacokinetics of vancomycin administered via continuous infusion and 
found that high loading (35 mg/kg) and maintenance (35 mg/kg/day) doses were needed to 
rapidly achieve therapeutic vancomycin concentrations of 20 mcg/mL among critically ill 
patients.[87] Additional studies are needed to determine whether larger doses of 
vancomycin administered via continuous infusion affect mortality or the time to clinical 
and microbiological response. However, a report by Ingram et al. suggests that there may 
be an upper limit for steady-state vancomycin concentrations (≥28 mcg/mL) beyond which 
toxicity was frequently noted.[88] 
 
Special Populations 
Neonates and Infants 
 Establishing appropriate vancomycin dosing regimens for neonates and infants is 
challenging due to physiological and developmental factors that contribute to high 
pharmacokinetic variability.[89] For example, neonates have a high proportion of water by 
weight and rapidly changing renal function in the post-natal period, all of which have the 
potential to alter vancomycin pharmacokinetics.[90] These factors change most rapidly 
during the first week of life.[90] 
Although many studies have investigated vancomycin pharmacokinetics in 
neonates and infants, an optimal dosing regimen has not yet been evaluated clinically.[34, 
90] Variation in vancomycin clearance among pre-term (gestational age <37 weeks) and 
term (≥37 weeks gestation) neonates has been shown to be influenced by weight, post-
menstrual age, and renal function.[91-94] This is reflected in the wide range of vancomycin 
half-lives (2-12 hours) reported among neonates.[90, 95] Population pharmacokinetic 
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studies have been reported to improve the likelihood of achieving target vancomycin 
concentrations among neonates.[96] Although two-compartment models with a long 
distribution phase best reflect vancomycin pharmacokinetics, one-compartment models 
perform reasonably well in providing individual pharmacokinetic parameter estimates that 
may be used for the purpose of developing individualized neonatal dosing regimens.[89, 
97] An added advantage of this approach is the ability to determine vancomycin 
pharmacokinetic parameters while obtaining relatively few blood samples.[89] Post-hoc 
dose adjustments are frequently required to achieve target concentrations due to 
unexplained pharmacokinetic variability, which continues to make therapeutic drug 
monitoring essential despite advances in neonatal-specific population pharmacokinetic 
models.[90, 96] 
Few studies have been able to link neonatal vancomycin pharmacokinetic / 
pharmacodynamic targets with positive clinical outcomes.[98] Currently, neonatal dosing 
is based on trough concentration targets derived from studies involving adults receiving 
treatment for MRSA infections.[98] Translation of these targets to neonatal medicine is 
challenging due to the fact that MRSA infections are relatively rare.[97, 99] In this patient 
population, coagulase-negative S. aureus is the most commonly identified infectious 
organism, which may require alternative vancomycin dosing regimens and the use of 
different pharmacokinetic / pharmacodynamic targets.[97, 99] 
Recently, Zhao et al. evaluated vancomycin continuous infusion regimens for 
neonates and found that the regimens used varied widely, presumably owing to a paucity 
of pharmacokinetic data.[100] To address this need, the authors evaluated 116 neonates 
who received vancomycin via continuous infusion and found that 41% had therapeutic 
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vancomycin concentrations (15-25 mcg/mL). Moreover, the distribution of observed 
concentrations varied widely (range 5.1-61.5 mcg/mL). Using a one-compartment 
population pharmacokinetic model, the authors developed an optimized dosing regimen 
incorporating birth weight, current weight, postnatal age, and serum creatinine. In a 
prospective evaluation of this optimized regimen, 71% of the 58 neonates evaluated 
achieved the target range of 15-25 mcg/mL. However, the proportion that achieved an AUC 
/ MIC > 400 is unknown. 
 
Children and Adolescents 
Similar to adults, the emergence of MRSA has led to a significant increase in the 
use of vancomycin among children.[101] Therapeutic target trough concentrations have 
rapidly evolved over the last decade.[8] Although treatment failure is rare, sub-therapeutic 
vancomycin trough concentrations (<5 mcg/mL) have been reported to be associated with 
a heightened risk for treatment failure.[102-104] Collectively, reports of rare treatment 
failures, inconsistent target attainment rates, and the absence of a clear causal relationship 
between vancomycin concentrations and toxicity in pediatric patients has led to upward 
revisions in pediatric dosing recommendations from several leading professional 
societies.[105-107] 
After two years of age, without allometric scaling, weight-related vancomycin 
clearance declines with increasing age and serum creatinine concentration.[108] Dosing 
regimens that account for the influence of age, serum creatinine, and the susceptibility of 
the target organism (e.g., MIC) have been reported to improve target attainment rates 
among children.[108] This is particularly true for children <12 years of age, for which 
41 
 
higher doses are typically required, and also for critically ill children who require 
admission to the pediatric intensive care unit.[107, 109] 
Pediatric therapeutic drug monitoring is common and is primarily based on trough 
concentration targets.[8] Current guideline recommendations suggest targeting steady state 
troughs >10 mcg/mL, with 15-20 mcg/mL recommended for the treatment of invasive 
MRSA infections.[8] These targets reflect a change in the primary motivation for 
vancomycin therapeutic drug monitoring, which is now less focused on detecting toxicity 
and more focused on ensuring that vancomycin concentrations are likely to be 
therapeutic.[110] It must be noted, however, that these targets are extrapolated from adult 
studies and may not directly correlate with pediatric outcomes.[110] Consequently, several 
institutions are in the process of re-evaluating their pediatric vancomycin therapeutic drug 
monitoring practices and are shifting away from the use of troughs exclusively in an effort 
to establish AUC-based dosing regimens, which have the potential to better describe 
vancomycin exposure over the entire dosing interval.[111] Frymoyer et al. determined that 
between 75-90% of children with vancomycin trough concentrations of approximately 7-
10 mcg/mL achieve an AUC / MIC >400 when the MIC is ≤1 mcg/mL.[101, 109] 
However, no studies have evaluated the rate of treatment failure among children with 
MRSA infections with trough concentrations of 7-10 mcg/mL and MICs ≤1 mcg/mL, 
which has led to wide variations in pediatric therapeutic drug monitoring and vancomycin 






 The clinical pharmacokinetics of many antimicrobials, including vancomycin, are 
altered among the elderly.[114] This occurs principally due to a decrease in renal clearance 
that occurs with increasing age and is characterized by a prolonged half-life and increased 
AUC.[114] These changes may be amplified among patients with severe infections who 
are prescribed nephrotoxic agents. 
In a study by Cutler et al., the pharmacokinetics of vancomycin were investigated 
in six healthy elderly men (61-77 years of age) and six healthy, young men (20-26 years of 
age).[115] It was reported that these individuals had an increased volume of distribution, 
increased tissue binding (calculated indirectly), an increased half-life, and significantly 
reduced vancomycin clearance.[115] However, the coefficients of variation for the derived 
pharmacokinetic parameters were relatively low (14-16%), suggesting that this relatively 
homogeneous population may not accurately reflect the true variability in vancomycin 
pharmacokinetics among elderly patients who are receiving vancomycin for the treatment 
of invasive MRSA infections. Guay et al. evaluated 148 elderly patients (≥60 years of age) 
who received vancomycin for the treatment of suspected or documented gram-positive or 
mixed infections.[116] The authors observed a significant increase in the volume of 
distribution, half-life, and a decreased rate of vancomycin clearance when compared to 
younger adults. In their population pharmacokinetic model, it was determined that 
advanced age was a strong predictor of vancomycin clearance, half-life, and volume of 
distribution. Due to these effects, it was established that elderly patients with normal renal 
function (serum creatinine values ≤1.5 mg/dL) require smaller daily doses as compared 
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with younger patients (18-59 years) to maintain similar target peak and trough 
concentrations (18.2 ± 5.8 vs. 25.2 ± 7.8 mg/kg/day). 
Recently, Mizokami et al. studied 94 elderly patients (75-99 years) with hospital-
acquired MRSA pneumonia and compared their clinical outcomes using trough- and AUC-
based vancomycin therapeutic drug monitoring methods.[117] The authors found that 
trough concentrations were not predictive of 28-day mortality, whereas an AUC <250 or 
>450 mcg*hr/mL was strongly associated with an increased risk of death (odds ratio 23.2, 
95% confidence interval 6.8-78.7). However, the authors did not report the method used to 
identify these thresholds (e.g., classification and regression tree analysis). Additionally, 
this retrospective study had a relatively small number of survivors with an AUC / MIC 
>450 (n = 11) and those who did not survive had more severe infections, which makes it 
difficult to determine whether a target AUC / MIC of 250-450 mcg*hr/mL improves 
treatment outcomes for elderly patients with hospital-acquired MRSA pneumonia. 
 
Obese Patients 
 A limited number of studies have investigated vancomycin pharmacokinetics 
among morbidly obese individuals. Bauer et al. evaluated morbidly obese and non-obese 
individuals and found that vancomycin clearance rates were similar (1.2 mL/min/kg vs. 1.1 
mL/min/kg, respectively).[118] The authors recommended that the total daily dose of 30 
mg/kg total bodyweight be divided every 6 or 8 hrs.[118] Similarly, Blouin et al. found no 
difference with respect to vancomycin clearance when clearance was expressed per kg of 
total bodyweight.[28] Additionally, they recommended that the total daily dose should be 
divided every 4 or 6 hrs to prevent high peak concentrations, which are associated with a 
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heightened risk for nephrotoxicity.[28] In accordance with these results, Vance-Bryan et 
al. reported that total bodyweight had a significant influence upon vancomycin clearance 
and volume of distribution in a study cohort in which 47% of the patients were obese.[119] 
As a consequence of the lack of difference in clearance per kg bodyweight, all reports have 
concluded that vancomycin should be dosed on total bodyweight with total daily doses 
varying from 20-30 mg/kg. 
Review articles evaluating vancomycin dosing in obese individuals have primarily 
summarized the above mentioned clinical studies, all of which emphasize the need for 
dosing regimens to be based upon total bodyweight and for dosing three or more times per 
day.[120-123] As vancomycin target concentrations are now higher than those targeted at 
the time that these studies were published it seems reasonable that obese individuals should 
now receive a total daily dose of at least 37.5 mg/kg divided three times per day to prevent 
potentially toxic high peak concentrations. When individual doses exceed 1 g (e.g., 1.5 and 
2 g), the infusion period should be extended to 1.5-2 hrs.[75] If vancomycin is administered 
by continuous infusion, a dose of 30 mg/kg/day is expected to result in exposures similar 
to those achieved with three intermittent infusion doses of 12.5 mg/kg. To rapidly reach 
steady state, a loading dose of 25 mg/kg may be considered.[75] Therapeutic drug 
monitoring is recommended for all morbidly obese individuals, even when there is no 
evidence of renal insufficiency. Prospective clinical studies are needed to evaluate these 
dosing proposals for morbidly obese individuals in light of the increased target vancomycin 





Patients with Cancer 
 Patients with cancer frequently receive empiric vancomycin for episodes of febrile 
neutropenia and courses of definitive therapy for the treatment of infections caused by 
gram-positive organisms.[124] As patterns of vancomycin use have adapted to relatively 
recent recommendations that target higher pharmacokinetic / pharmacodynamic targets, 
patients with cancer are at a disadvantage owing to their more rapid clearance when 
compared to adults, children, and elderly patients without cancer.[8, 125-131] In a 
vancomycin pharmacokinetic / pharmacodynamic study conducted among adults with 
hematologic malignancies, it was found that only patients with normal renal function who 
received a standard 2 g/day dose achieved therapeutic vancomycin concentrations.[132] 
Among children with cancer, Krivoy et al. reported an increase in vancomycin clearance 
and lower trough concentrations when compared to children without cancer.[130] On the 
basis of these findings, high vancomycin doses are recommended for patients with 
cancer.[124] 
Large vancomycin doses are required to achieve therapeutic concentrations for 
patients with cancer; however, patients with cancer are at an elevated risk for 
nephrotoxicity and warrant close monitoring.[133] Recognition of the potential for additive 
nephrotoxicity due to the use of vancomycin and the co-prescribing of other nephrotoxic 
agents (e.g., chemotherapy, cyclosporine, aminoglycosides, etc.) often leads to the use of 
low vancomycin doses (e.g., 1 g every 12 hrs for adults), which increases the risk for 
treatment failure and the emergence of resistance.[133] Moreover, patients with cancer are 
more likely to have less susceptible S. aureus isolates.[134] Rolston et al. tested the in vitro 
activity of vancomycin against 392 gram-positive isolates from patients with cancer and 
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found that 100% of the MRSA isolates and 98% of the MSSA isolates had MICs ≥1 
mcg/mL, which has been strongly associated with treatment failure.[134] 
There are major limitations associated with extrapolations from small, retrospective 
analyses often based solely on vancomycin trough concentrations. Consequently, there is 
a need for prospective, disease-specific population pharmacokinetic / pharmacodynamic 
studies to determine whether patients with cancer have an altered vancomycin 
pharmacokinetic profile. Currently, therapeutic drug monitoring is essential to 
individualize vancomycin therapy, thereby balancing therapeutic efficacy with the 
potential for developing toxicity among patients with cancer. 
 
Continuous Renal Replacement Therapy 
Multiple studies have examined the effect of continuous renal replacement therapy 
(CRRT) on vancomycin pharmacokinetics in critically ill patients.[87, 135-138] Many of 
these arrived at conflicting results regarding the influence of CRRT on vancomycin 
clearance and volume of distribution. DelDot et al. evaluated 10 critically ill patients 
receiving continuous venovenous hemodiafiltration (CVVHDF) and found that the mean 
total body clearance of vancomycin was 2.5 ± 0.7 L/hr, whilst that cleared by CVVHDF 
was 1.8 ± 0.4 L/hr (76% of total body clearance).[135] Another vancomycin 
pharmacokinetics study conducted among patients undergoing continuous venovenous 
hemofiltration (CVVH) found that CVVH represented approximately 50% of total 
vancomycin clearance.[139] Additionally, varying volume of distribution estimates have 
been reported.[87, 136] Theoretically, it is expected that the pathophysiology of acute 
kidney injury would result in impaired water and solute excretion, which would result in a 
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larger extracellular fluid compartment and lead to an increase in the volume of 
distribution.[140] In one of the largest studies to date this was not found to occur; however, 
the authors acknowledge that they were unable to account for fluid maintenance in the 
intensive care unit, which likely represents a critical covariate needed to accurately model 
vancomycin pharmacokinetics for this patient population.[136] 
In a recent study, Covajes et al. evaluated 85 patients requiring CRRT and 
determined that higher vancomycin doses were needed for patients with the highest CRRT 
intensity (>40 mL/kg/hr).[141] The authors targeted a steady state concentration of 20-30 
mcg/mL and reported that the two significant factors that influenced vancomycin target 
attainment rates within the first three days of therapy were the daily dosage amount and 
the intensity of CRRT. On day one of therapy, 51% of patients had adequate steady state 
vancomycin concentrations, 20% had supra-therapeutic concentrations, and 29% had sub-
therapeutic concentrations. The majority of patients with adequate steady state vancomycin 
concentrations received a daily dose of 16-35 mg/kg. Due to the rapid evolution of acute 
kidney injury and the potential for rapid deterioration, therapeutic drug monitoring should 
be performed as early as 6 hours after administration of the first vancomycin dose, with 
maintenance dosing established after additional samples have been drawn.[142] This is 
especially critical as up to 49% of patients undergoing CRRT have been reported to have 
sub-therapeutic vancomycin concentrations.[143] Moreover, as the duration of CRRT 
increases non-renal clearance decreases, eventually approaching vancomycin clearance 
rates observed in patients with chronic renal failure.[50] Due to high variability in non-
renal clearance over time, individualized vancomycin dosing regimens are essential for 
patients with acute renal failure.[50] 
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Patients with Cystic Fibrosis 
The prevalence of pulmonary MRSA infections has increased among patients with 
cystic fibrosis.[144, 145] In 2008, the Cystic Fibrosis Foundation reported that 50% of 
patients with cystic fibrosis were infected with S. aureus and 23% were infected with 
MRSA.   Among patients with cystic fibrosis, MRSA is primarily isolated from children 
and young adults.[147] 
Pleasants et al. evaluated vancomycin pharmacokinetics among 10 adults with 
acute pulmonary exacerbations of cystic fibrosis.[148] The volume of distribution, total 
body clearance, and terminal elimination rate were similar among patients with cystic 
fibrosis when compared to previous pharmacokinetic parameter estimates derived from 
studies with healthy adult volunteers.[148, 149] However, Stockmann et al. found that 
vancomycin clearance was slower among children with cystic fibrosis (0.08 L/hr/kg) when 
compared to children without cystic fibrosis (0.10-0.16 L/hr/kg).[150-153] It is unclear 
whether lower vancomycin doses are needed to accommodate the decreased clearance 
among children with cystic fibrosis; however, vancomycin may be dosed similarly for 
adults with and without cystic fibrosis. As for all patients, therapeutic drug monitoring is 
highly recommended to prevent sub-therapeutic dosing and toxicity.[8] 
 
Critically Ill Patients 
Critically ill patients are an inherently heterogeneous population with varying 
extents of organ dysfunction, often requiring mechanical support for failing organ systems, 
and the administration of many life-saving medications.[52] All of these factors may 
modify the pharmacokinetic profile of vancomycin. 
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Llopis-Salvia et al. conducted a population pharmacokinetic study among 50 
critically ill adults who required vancomycin for the treatment of suspected or proven 
gram-positive infections.[52] The authors used a two-compartment model and determined 
that the total body clearance for a 60 kg patient was 60 mL/min, with approximately 28% 
occurring via non-renal mechanisms. The volume of distribution in the central and 
peripheral compartments were estimated as 0.41 and 1.32 L/kg, respectively, and were 
linearly related to total body weight. In contrast, Rodvold et al. reported a volume of 
distribution in the central compartment of 0.21-0.24 L/kg in a population of patients with 
renal dysfunction.[154] The increased volume of distribution among critically ill patients 
may be explained, at least in part, by the physiologic changes in body compartments that 
occur as a consequence of fluid overload and/or from the accumulation of fluid in the third 
space due to tissue edema.[155] 
A Bayesian pharmacokinetic approach has been proposed to feature excellent 
predictive performance in evaluating vancomycin dosing regimens for critically ill 
patients.[52, 156] Ito et al. developed a two compartment vancomycin infusion algorithm 
that resulted in a mean bias of 7.7 ± 7.6 mcg/mL and a mean precision of 8.9 ± 6.2 mcg/mL 
for estimating vancomycin trough concentrations.[156] More recently, Llopis-Salvia et al. 
established a Bayesian model that yielded improved predictive performance with regard to 
both the trough bias (-0.2 mcg/mL) and precision (3.9 mcg/mL).[52] 
Current guidelines recommend that vancomycin be administered via intermittent 
infusion; however, some investigators prefer continuous infusion, particularly for critically 
ill patients.[74, 157, 158] For septic patients with a large volume of distribution continuous 
infusion may be preferable.[52, 159, 160] Saugel et al. retrospectively evaluated 164 adults 
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admitted to their medical intensive care unit and reported that a vancomycin continuous 
infusion regimen with a median daily dose of 960 (95% confidence interval 526-1723) mg 
resulted in a median vancomycin concentration of 19.8 (9.8-29.4) mcg/mL.[161] Using a 
target of 15-25 mcg/mL, the authors found that serum vancomycin concentrations were 
frequently sub-therapeutic on day one (44%), day two (29%), and day three (23%). These 
findings suggest that therapeutic drug monitoring is essential to ensure attainment of 
therapeutic vancomycin concentrations. Moreover, it may be speculated that higher doses 
may be necessary for critically ill patients. 
 
Expert Commentary and Five-Year View 
 More than 50 years after the discovery of vancomycin, dosing regimens continue 
to evolve. Historically, pharmacokinetic / pharmacodynamic targets have been based on 
the use of trough concentrations, which are crude surrogates that are unable to capture the 
overall shape and extent of drug exposure over the entire dosing interval.[102] Within the 
last five years there has been a movement toward AUC-based therapeutic drug monitoring, 
which is a more accurate representation of vancomycin exposure.[75] Over the next five 
years, we expect that pharmacokinetic and pharmacodynamic models will continue to be 
vital tools used to establish targets for the treatment of invasive MRSA-associated 
bacteremia, osteomyelitis, skin and soft tissue infections, and meningitis. Moreover, we 
expect that studies will evaluate the AUC/MIC >400 target that is currently recommended 
for adults with MRSA-associated lower respiratory tract infections in other patient 
populations, which may feature altered vancomycin pharmacokinetic profiles.[74] 
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In addition to their utility in establishing therapeutic targets, these pharmacokinetic 
/ pharmacodynamic models may be used to evaluate the efficacy and safety of alternative 
vancomycin administration methods. Currently, fewer than 50% of neonates reach 
therapeutic vancomycin concentrations with guideline-recommended intermittent dosing 
regimens.[97, 162] The reasons for this are likely to be multifactorial and may include:  
uncertainties regarding an appropriate therapeutic concentration; developmental 
considerations related to the acquisition of renal function; differences in the etiological 
agents of neonatal sepsis; unknown vancomycin concentrations at the site of action; and an 
unclear mechanism for vancomycin-induced nephrotoxicity, all of which contribute to the 
need for prospective, clinical trials guided by population pharmacokinetic / 
pharmacodynamic modeling.[98] 
Continuous infusion of vancomycin is increasingly being used for adults with 
invasive MRSA infections; however, many studies report differing vancomycin target 
concentrations.[85] Further research is needed to establish a link between clinical outcomes 
and steady state vancomycin concentrations achieved with continuous infusion regimens. 
With such data, it would be possible to develop pharmacokinetic / pharmacodynamic 
models to identify optimal dosing regimens that would be likely to achieve positive clinical 
outcomes by maximizing the likelihood of attaining desired vancomycin target 
concentrations. In the event that this occurs within the next five years, it will be critical to 
evaluate whether such dosing regimens are appropriate for other patient populations, for 
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POPULATION PHARMACOKINETICS OF INTERMITTENT 
VANCOMYCIN IN CHILDREN 
WITH CYSTIC FIBROSIS 
 
Abstract 
 Background: Vancomycin is the drug-of-choice for the treatment of methicillin-
resistant Staphylococcus aureus (MRSA) infections in children with cystic fibrosis. 
However, no studies have characterized the pharmacokinetic profile of vancomycin among 
pediatric cystic fibrosis patients. 
Objective: To evaluate the pharmacokinetics of intermittent vancomycin 
administration in children with cystic fibrosis and identify covariates that significantly 
influence vancomycin efficacy and safety. 
Methods: Therapeutic drug monitoring data were obtained from two cystic fibrosis 
care centers that identified children <18 years who received vancomycin treatment for an 
acute pulmonary exacerbation from 2005-2010. Trough and peak serum concentrations 




were developed to evaluate the population pharmacokinetics of vancomycin. 
Results: Among the 67 children (mean age 12.1+5.3 years), the mean vancomycin 
dose was 17.4+4.4 mg/kg. The mean trough concentration (Cmin) was 10.3+3.8 mg/L. The 
mean daily area under the serum concentration time curve (AUC24) was 282.5+816.9 
mg*hr/L. A one-compartment model with first-order elimination best described the data. 
Weight significantly influenced vancomycin clearance (P<0.001). In the final model, 
clearance was estimated as 5.57 L/hr/70 kg, and the volume of distribution was 44.1 L/70 
kg. The between subject variabilities for clearance and volume of distribution were 27% 
and 40%, respectively. 
Conclusions: Using a one-compartment model to evaluate the pharmacokinetic 
properties of vancomycin in children with cystic fibrosis, clearance increased with body 
weight. Pharmacodynamic studies are needed to establish an optimal vancomycin dosing 
regimen for the treatment of pediatric exacerbations of cystic fibrosis. 
 
Background 
Vancomycin is commonly used to treat severe methicillin-resistant Staphylococcus 
aureus (MRSA) infections and has been widely studied in adults.[2] The prevalence of 
MRSA lower respiratory tract infections in patients with cystic fibrosis (CF) is 
increasing.[3-5]  From 1996 to 2006, the proportion of patients with CF who had one or 
more positive culture(s) for MRSA increased from 2% to 19%.  According to the 2008 
Cystic Fibrosis Foundation (CFF) Patient Registry, more than 50% of patients with CF are 
infected with S. aureus, and 23% are infected with MRSA.6,7  Among patients with CF, 
MRSA is primarily isolated from children and young adults.[8] 
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The importance of proper vancomycin dosing has been highlighted in a consensus 
national guideline endorsed by several leading professional societies.[2]  Guideline 
recommendations were supported by data from adults without CF.  Pharmacokinetic data 
to guide the optimal dosing of vancomycin in patients with CF are limited across all age 
groups.  A small pharmacokinetic analysis of vancomycin in 10 adults with CF was 
published in 1996.[9]  This study found that the disposition and pharmacokinetics of 
vancomycin were similar in adults with CF and healthy adult volunteers.  However, there 
is a critical shortage of pharmacometric data for children and young adults with CF, who 
are most frequently infected with MRSA. 
Although MRSA possesses virulence factors that can damage host tissue, the 
clinical consequences of MRSA infection in children with CF are poorly understood.[10, 
11] In a large observational study, Ren et al. reported that patients who were culture-
positive for MRSA had greater airway obstruction compared with patients with methicillin-
sensitive S. aureus (MSSA).[12] A follow-up study found that despite greater airway 
obstruction, aggressive treatment with antibiotics, and more frequent hospitalizations, the 
rate of lung function decline was not significantly different for patients with MRSA or 
MSSA.[13] However, Dasenbrook and colleagues retrospectively examined 19,833 
patients with CF and found evidence of an increased risk of death among patients with 
MRSA infection versus patients with MSSA infection.[14]  
The objective of this study was to characterize the pharmacokinetic parameters of 
vancomycin in a population of children recruited from two CF care centers.  Potential 





Setting and Study Population 
This retrospective study consisted of 67 pediatric patients who received 
vancomycin for treatment of a CF pulmonary exacerbation.  Children who received 
treatment at Intermountain Primary Children’s Medical Center, Salt Lake City, Utah and 
Cardinal Glennon Children’s Medical Center, St. Louis, Missouri from January 1, 2005 
through December 31, 2010 were eligible for inclusion.  Patient demographics, including 
age, sex, weight, height, and serum creatinine were recorded through a combination of 
electronic and manual abstraction from the medical record. This study was reviewed, 
approved, and granted a waiver of informed consent by Institutional Review Boards at both 
study sites. 
 
Drug Administration and Sample Collection 
 Intermountain Primary Children’s Medical Center and Cardinal Glennon 
Children’s Medical Center routinely evaluate for evidence of MRSA infection among 
children with CF undergoing treatment for an acute pulmonary exacerbation. Vancomycin 
is used as the first-line therapy for MRSA at both study sites.[15]  All patients received a 
60-minute infusion of vancomycin using a syringe pump at doses of 15-20 mg/kg 
administered 2, 3, or 4 times daily.  The mean dose was 16.5 + 4.2 mg/kg for patients 
treated at Intermountain Primary Children’s Medical Center and 17.9 + 4.5 mg/kg for 
patients treated at Cardinal Glennon Children’s Medical Center. Dosing adjustments were 
made for peak concentrations less than 20 mg/L, peak concentrations greater than 40 mg/L, 
and trough concentrations greater than 20 mg/L. 
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Blood samples were collected from all patients for therapeutic drug monitoring as 
part of routine medical care. Samples were drawn within 30 minutes before the dose 
(trough concentration) and 30 minutes after the end of the intravenous infusion (peak 
concentration). Treatment duration was typically 10 to 14 days, based on clinical status and 
pulmonary function testing results. 
 
Vancomycin Assay 
 Serum drug concentrations were measured using a fluorescence polarization 
immunoassay (Abbott  AxSYM, Abbott Park, IL).[16] Assay validation was performed for 
clinical purposes. The lower and upper limits of quantification were 2.0 mg/L and 100.0 
mg/L, respectively. At Cardinal Glennon Children’s Medical Center, the intra-day relative 
standard deviation (a measure of precision) ranged from 3.5-4.3% and the inter-day relative 
standard deviation ranged from 0.6-0.9%. The relative error (a measure of accuracy) ranged 
from 2.9-4.3%. At Primary Children’s Medical Center, the intra-day and inter-day relative 
standard deviations ranged from 4.7-7.1%.  
 
Pharmacokinetic Analysis 
 Vancomycin pharmacokinetic parameters were evaluated using NONMEM 7.2 
(non-linear mixed effects modeling; ICON Development Solutions, Ellicott City, MD).  
Data from the two centers were initially assessed separately.  Results were found to be 
comparable, and the data were pooled for all further analyses.  Pooled data were fitted with 
one- and two-compartment first-order conditional estimation with interaction models.  The 




Structural models were selected for further assessment using the Akaike 
information criterion (AIC) and the Schwarz Bayesian criterion (SBC).[17]  Diagnostic 
plots were used to visually inspect the model’s fit, including observed vs. population 
predicted vancomycin concentrations and observed vs. individual predicted vancomycin 
concentrations.  Residuals and conditional weighted residuals (CWRES) were also plotted 
vs. time or population predicted vancomycin concentrations.  Models were further 
compared by assessing the precision of the parameter estimates, measures of variability, 
and the objective function value (OFV).  A reduction in the OFV of more than 5.99 (-2 log 
likelihood difference) was considered to be statistically significant with two degrees of 
freedom and a P<0.05.[18] 
Model variability and random effects were classified as one of two types of error:  
1) between-subject variability (BSV) and 2) residual unexplained variability (RUV).  BSV 
is the variability inherent between different patients and was assumed to be log-normally 
distributed according to an exponential equation of the form: 
𝑃𝑖 = 𝜃𝑝𝑜𝑝 ∗ exp(𝜂𝑖
𝜃) ;         𝜂𝑖
𝜃 i. i. d. ~ N(0, ω𝜃
2 ) (3.1) 
where Pi is the value of the pharmacokinetic parameter for the ith individual, θpop is the 
population mean for P, and ηiθ represents the between subject random effect for the ith 
individual on θ, each of which are independent and identically distributed with a mean of 
zero and a variance of ω2.[19] 
The RUV was the second source of variability and reflects the difference between 
the model prediction for the individual and the measured observation.  This includes the 
error in the assay, errors in drug dose, errors in the time of measurement, etc.[20]  During 
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model development, RUV was evaluated using additive, proportional, and combined error 
models.  A combined residual error model resulted in the greatest improvement in the OFV. 
The equation for the combined error model was: 
𝑌𝑖𝑗 = 𝑌𝑚𝑖𝑗(1 + 𝜀𝑖𝑗) + 𝜀𝑖𝑗 (3.2) 
where Yij is the observed concentration for the ith individual at time j, Ymij is the model 
prediction, and εij is a normally-distributed random error with a mean of zero and a variance 
of σ2. 
The area under the plasma concentration vs. time curve over a day (AUC24) for 








Potential covariates were initially identified through generalized additive modeling. 
Further testing was performed by evaluating potential covariates using stepwise forward 
addition and then stepwise backward elimination procedures. A reduction in the OFV of 
>5.99 (P<0.05) was required to retain covariates in the forward addition step. In the 
backward elimination step, covariates were retained if they resulted in a reduction in the 
OFV of >9.21 (P<0.01).  
Age, weight, height, sex, and serum creatinine were included in the covariate 
analysis.  To adjust for differences in body size and metabolic rate, allometric scaling was 
applied to standardize body weight between the parameter estimates determined for this 
pediatric population and values reported for a typical 70 kg adult by fixing the exponents 
in the allometric model to 0.75 for clearance (equation 3) and to 1 for the VD.[21] 
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) ∗ exp(𝜂𝐶𝐿) 
(3.4) 
where CLi is the individual clearance in the ith individual, CLpop is the estimate of the 
population clearance, 𝜂𝐶𝐿 is the random between subject variability, θ is the shift parameter 
describing the systematic dependence of clearance on individual body weight, and BW is 
the body weight of the ith individual. 
 
Model Evaluation 
 Models were evaluated and selected based on the goodness of fit and unstable 
models were excluded from the model building process.  The stability of the models was 
assessed by changing the number of significant digits and the initial parameter estimates 
for CL and VD. Models were also compared using the Akaike information criterion (AIC) 
and Schwarz information criterion (SIC) to discriminate between non-hierarchical models 
as part of the model selection criteria.[17] Nonparametric bootstrapping techniques were 
utilized to evaluate the stability of the final pharmacokinetic model and to quantify the 
uncertainty in parameter estimates.[22]  PDx-Pop was used to derive 1000 bootstrap runs 
by randomly sampling with replacement from the original dataset.  Standard errors were 
computed for both the estimated population parameters and random effect error models.  
Model stability was further assessed by generating visual predictive checks, in which the 
90% confidence interval from the measured vancomycin concentrations were compared to 






Patients and Pharmacokinetics 
The median age of the study population was 13.9 years (interquartile range:  8-17), 
and a majority of patients were female (60%). The mean body weight of the patients was 
40.6 + 19.5 kg.  Additional demographic characteristics are summarized in Table 3.1. From 
these 67 patients, there were 227 unique hospitalizations. Cardinal Glennon contributed 
337 vancomycin concentration measurements (mean 7.9 + 9.6 concentrations per patient), 
and Intermountain Primary Children’s Medical Center contributed 149 (mean 6.3 + 6.8 
concentrations per patient). The mean peak (Cmax) and trough (Cmin) vancomycin 
concentrations were 25.4 + 11.0 mg/L and 10.1 + 3.8 mg/L, respectively. The mean AUC24 
was 282.5 + 816.9 mg*hr/L. 
 
Population Pharmacokinetic Models 
 Several structural models were explored to determine the model that best fit the 
vancomycin concentration data.  One-compartment and two-compartment structural 
models with first-order elimination were assessed with additive, proportional, and 
combined error models.  Structural models also incorporated the rate and duration of the 
IV infusion for each subject. 
A one-compartment model was used to describe the serum concentrations of 
vancomycin in this patient population. The base model was a one-compartment model with 
first-order elimination, which was selected as the initial base model on the basis of the 
OFV, AIC, and SBC.  Base model parameter estimates for CL were similar for the Cardinal 
Glennon and Intermountain Primary Children’s models, 2.38 and 3.24 L/hr, respectively. 
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Table 3.1. Demographic characteristics among children with cystic fibrosis who received 











Age, yrs    
Median 14 12.5 13.9 
Interquartile range 9 – 17 7.1 – 15.5 8 – 17 
Sex    
Male 19 (44) 8 (33) 27 (40) 
Female 24 (56) 16 (67) 40 (60) 
Weight, kg    
Median 43.2 36.6 41.2 
Interquartile range 27.1 – 59.9 23.1 – 46.8 25.5 – 56.8 
Height, cm    
Median 154 140 150 




Similarly, the base model estimates for VD were 46.6 and 18.6 L for the Cardinal Glennon 
and Intermountain Primary Children’s data, respectively.  Due to the similarity of these 
estimates, data from the two centers were combined for a pooled analysis.  The base model 
estimated CL as 2.70 L/hr and VD as 44.8 L for the pooled analysis. 
A covariate analysis was undertaken in which each covariate was added to the 
model.  Following univariate analyses, weight (P<0.001) and serum creatinine (P<0.05) 
were identified as having a significant influence on vancomycin pharmacokinetics.  
However, in multivariate analyses accounting for weight, serum creatinine had no 
significant influence.  The inclusion of allometric scaling significantly improved the OFV 
(P<0.001).  This model determined that vancomycin clearance increased with increasing 
weight. 
The final covariate model was chosen as it produced the most significant 
minimization of the OFV (Δ 37.9), reduced the BSV, and decreased the RUV.  The 
parameter estimates derived from the final covariate model are shown in Table 3.2.  Also 
presented are several metrics used to assess the stability and robustness of the final model 
including standard errors, coefficients of variation, 95% confidence intervals, and 
bootstrapped estimates (n=1000). The 95% confidence interval surrounding the 
bootstrapped point estimate for the BSV in VD includes 0. 
 
Model Evaluation 
Diagnostic plots were generated for assessing model fit between observed 
vancomycin concentrations versus population predicted and individual predicted values 













































































































































































































































































































































































































































































































































conditional estimation method) versus the population predicted vancomycin concentrations 
were also examined (Figure 3.1).  In aggregate, visual inspection revealed that the final 
covariate model fit the data more tightly than the initial base model, indicating superior 
performance. 
Bootstrapping techniques were also used to assess the robustness of the final 
covariate model.  Mean estimates from the 1000 bootstrap runs were similar to the 
population estimates derived from the final covariate model.  Bootstraps were successfully 
generated 88% of the time for the pooled data from both Cardinal Glennon and 
Intermountain Primary Children’s Medical Center.  Simulations from the final covariate 
model were derived from the observed vancomycin data in an effort to reveal evidence of 
model misspecification, which is not easily detected by other methods.[23]  Visual 
predictive checks (VPC) present a graphical comparison of the observed vancomycin data 
and simulated data and are shown in Figure 3.2, with the median simulated value compared 
to the 5th, 10th, 90th, and 95th quantiles.  Of the 48,600 simulated observations 93% fell 
within the 90% confidence interval of the observed vancomycin concentrations, 
demonstrating reasonable model stability and agreement. 
 
Discussion 
 Monitoring of vancomycin concentrations is common to prevent sub-therapeutic 
dosing and toxicity.[24] Despite extensive study among other patient populations,[25-27] 
vancomycin population pharmacokinetics have not been described for children with CF.  
In this study, vancomycin CL and VD were estimated using a one-compartment model with 
data derived from children with CF from two centers.  Vancomycin CL increased with   
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Figure 3.1. Diagnostic plots of the final model. (A) Observed versus population-predicted 
vancomycin concentrations; (B) observed versus individual-predicted vancomycin 
concentrations; (C) conditional weighted residuals versus population-predicted 
vancomycin concentrations; and (D) conditional weighted residuals versus the time after 

































































































































































































increasing weight and is an important covariate that merits consideration in establishing 
initial dosing regimens for children with acute pulmonary exacerbations of CF. 
The pathophysiology of CF affects the pharmacokinetics of many antibacterials 
prescribed for the treatment of acute pulmonary exacerbations.[28, 29]  To evaluate 
whether vancomycin dosage requirements differ between patients with CF and those 
without, Pleasants et al. evaluated the pharmacokinetics of vancomycin among 10 adults 
with CF.[9]  The authors reported pharmacokinetic parameter estimates that were similar 
to earlier studies among healthy adult volunteers.  In an earlier study that evaluated 
vancomycin pharmacokinetics among adults with burn injuries, CL was estimated as 5.3 
L/hr/70 kg.[30]  This compares favorably with our CL estimate of 5.57 L/hr/70 kg.  Among 
56 adults with varying levels of renal impairment, the mean VD at steady-state was 0.72 
L/kg.[31]  The mean VD among our cohort of pediatric patients with CF was 0.63 L/kg.  
These findings suggest that vancomycin pharmacokinetics in children are not substantially 
different from values that have been reported in adult populations with normal to minor 
renal impairment.  In contrast, vancomycin CL among children without CF has been 
reported to range from 0.10 to 0.16 L/hr/kg.[32-34]  It is possible that the relatively young 
ages of the children included in these studies (mean ages of 3.9, 5.6, and 7.6 years, 
respectively) or the pathophysiologic changes that result from CF may account for the 
difference between the CL estimate of 0.08 L/hr/kg reported here among a population of 
slightly older children (mean age of 12.1 years).  Despite this, the mean VD in the present 
population was 0.63 L/kg, which is similar to estimates obtained in several earlier studies 
conducted among different populations of children without CF.[32-35]  In aggregate, these 
data support the notion that vancomycin CL among older children with CF may more 
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closely resemble adult CL estimates, while the VD of vancomycin is similar to values 
reported among healthy children. 
In the present study, current body weight was an important covariate that influenced 
vancomycin clearance among children with CF.  Previous studies in both children and 
adults without CF have also identified current weight as an important determinant of 
vancomycin pharmacokinetics.[36, 37] 
Controversy exists as to whether a one-compartment or a two-compartment model 
is more appropriate for characterizing vancomycin pharmacokinetics.[38]  Albrecht et al. 
reported that the half-life of vancomycin ranged from 0.2 to 0.8 hours.[39]  This led the 
authors to conclude that a one-compartment model using two serum concentrations is 
acceptable for pharmacokinetic modeling studies.[39]  In evaluating a Bayesian approach, 
Pryka et al. assessed the relative predictive utility of one- and two-compartment models 
and determined that a two-compartment model was more precise and less biased.[40]  
However, Rosell et al. proposed that it is difficult to ethically-justify the number of serum 
concentrations needed to rigorously evaluate a two-compartment model.[41]  In clinical 
practice, post-distributive vancomycin concentrations are frequently obtained, which allow 
the use of one-compartment model equations to describe the pharmacokinetics of a two-
compartment drug.[42]  This study utilized data that were collected during routine 
therapeutic drug monitoring and therefore featured a limited number of vancomycin 
concentrations for each patient.  With the limited data available, we found that a one-
compartment model tended to under-predict low vancomycin concentrations and over-
predict high concentrations among children with CF.  It is likely that more frequent 
sampling may have supported the use of a two-compartment model. 
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Interpretation of these findings is subject to several limitations.  Data were collected 
during routine therapeutic drug monitoring, and a limited number of vancomycin 
concentrations were measured for each patient.  Additionally, this study was not designed 
to correlate vancomycin pharmacokinetics with clinical efficacy, although trough 
concentrations of <10 mg/L have been associated with treatment failure, which may be due 
to poor tissue penetration and selection of vancomycin-heteroresistant S. aureus.[43]  This 
emphasizes the importance of achieving appropriate vancomycin serum concentrations for 
each patient, which requires individualized dosing and knowledge of important covariates 
that influence vancomycin pharmacokinetics. 
The pathophysiology of CF has been reported to alter aminoglycoside 
pharmacokinetics, making it difficult to establish dosing regimens that optimize 
antibacterial efficacy and safety.[44]  As the prevalence of MRSA has increased over the 
last 30 years, vancomycin use has also increased.[45, 46]  Despite this, relatively little is 
known about the pharmacokinetics of vancomycin in children with CF.  In this study, 
vancomycin pharmacokinetics were adequately described with a one-compartment first-
order elimination model.  Vancomycin CL was lower than has been reported among studies 
of younger children without CF.  Clearance was also significantly influenced by current 
body weight.  The VD was similar among children with CF, healthy children, and 
heterogeneous adult populations.  Future pharmacodynamic studies are needed to establish 
markers of efficacy and safety, which may be used to develop an optimal vancomycin 
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PREDICTIVE PERFORMANCE OF A VANCOMYCIN 
POPULATION PHARMACOKINETIC  
MODEL IN NEONATES 
 
Abstract 
 Introduction: The pharmacokinetics of vancomycin are highly variable among 
neonates, which makes dosing challenging in this population. However, adequate drug 
exposure is critical, especially when treating methicillin-resistant Staphylococcus aureus 
(MRSA) infections. Utilization of population pharmacokinetic models and Bayesian 
methods offers the potential for developing individualized therapeutic approaches. To meet 
this need, a neonatal vancomycin population pharmacokinetic model was recently 
published. The current study sought to externally evaluate the predictive performance and 
generalizability of this model. 
Methods: A retrospective chart review of neonates who received vancomycin and 
had ≥1 peak and ≥1 trough concentrations at five Intermountain Healthcare neonatal 




cohort. The published population pharmacokinetic model was implemented in NONMEM 
7.2 with the structural and variance parameter values set equal to the estimates reported 
previously. The model was then used to predict the first peak and trough concentration for 
each neonate in the validation cohort and the model prediction error and absolute prediction 
error were calculated. Normalized prediction distribution errors (NPDE) were also 
evaluated. 
Results: A total of 243 neonates were studied with a median postmenstrual age of 
33 (interquartile range [IQR]:  28-39) weeks and a median weight of 1.6 (IQR:  1.0-2.9) 
kg. The model predicted the observed vancomycin concentrations with reasonable 
precision. For all vancomycin concentrations, the median prediction error was -0.8 (95% 
CI:  -1.4 to -0.4) mg/L and the median absolute prediction error was 3.0 (95% CI:  2.7 to 
3.5) mg/L. No trends in NPDE across weight, postmenstrual age, serum creatinine or time 
after dose were observed. 
Conclusions: An evaluation of a recently published neonatal vancomycin 
population pharmacokinetic model in a large external dataset supported the predictive 
performance and generalizability of the model. This model may be useful in evaluating 
neonatal vancomycin dosing regimens and estimating the extent of drug exposure. 
 
Introduction 
Optimizing vancomycin dosing to rapidly achieve adequate drug exposure is 
imperative in treating neonatal sepsis, particularly when treating invasive methicillin-
resistant Staphylococcus aureus (MRSA) infections.[1] However, this has been 
challenging in neonates as the pharmacokinetics of vancomycin are highly variable among 
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neonates due to developmental and pathophysiological changes.[2, 3] Recent studies have 
shown that standard neonatal vancomycin dosing strategies, such as those outlined in 
NeoFax®, do not reliably achieve trough concentrations >10 mg/L.[4, 5] In addition, the 
ratio of the 24-hour area under the concentration-time curve (AUC24) to the minimum 
inhibitory concentration (MIC) – the best predictor of successful outcomes when treating 
invasive MRSA infections – is not routinely utilized to assess the appropriateness of 
vancomycin dosing in neonates, presumably due to practical limitations associated with 
calculating the AUC24. 
Innovative vancomycin dosing strategies are therefore needed in neonates that 1) 
incorporate known patient-specific determinants of vancomycin pharmacokinetics such as 
size, maturation, and renal function in the dose selection and 2) allow for assessment of 
AUC24 based on the dosing history and vancomycin concentration(s) measured as part of 
routine therapeutic drug monitoring.[3, 6, 7] To develop such an individualized therapeutic 
approach in neonates, utilization of population pharmacokinetic models and Bayesian 
methods will be essential.[8-11] We recently developed a neonatal vancomycin population 
pharmacokinetic model that capitalized on patient data readily available in the electronic 
medical record:  weight (an indicator of size), postmenstrual age (an indicator of 
maturation), and serum creatinine (an indicator of renal function).[7] The model has the 
potential to improve our ability to define vancomycin dosing regimens that reliably achieve 
recommended exposure targets; however, it is critical to first evaluate whether this model 
and its findings are generalizable to neonates outside of the original population used to 
develop the model. The objective of the current study was to conduct an external evaluation 
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of this published pharmacokinetic model and to enhance our understanding of the 




Approval to conduct this study was granted by the University of Utah and Primary 
Children’s Hospital (PCH) Institutional Review Boards. PCH is a freestanding children’s 
hospital with a level IV neonatal intensive care unit that is staffed by University of Utah 
neonatologists. PCH is owned and operated by Intermountain Healthcare, which is a large, 
not-for-profit, vertically-integrated healthcare delivery system that serves Utah, Idaho, 
Wyoming, Nevada, and Montana. In addition to PCH, four other level II-III neonatal 
intensive care units operated by Intermountain Healthcare were included in this study. 
A retrospective chart review was conducted for all neonates who had vancomycin 
therapeutic drug monitoring performed from 2006-2013 at five Intermountain Healthcare 
neonatal intensive care units. Neonates were included if they were <54 weeks 
postmenstrual age and had ≥2 doses of vancomycin, ≥1 peak concentration, ≥1 trough 
concentration, and ≥1 serum creatinine level. Vancomycin concentrations were quantified 
using a particle-enhanced turbidimetric inhibition immunoassay on an Abbott Architect 
cSystem platform (Abbott Laboratories, Abbott Park, Illinois). Vancomycin concentrations 
were defined based on their temporal relationship to dosing records. Trough concentrations 
were defined as concentrations obtained within three hours of the next vancomycin dose 
and peak concentrations were defined as concentrations obtained within three hours of the 
preceding dose. Serum creatinine levels collected within ±48 hours of vancomycin dosing 
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and concentration records were carried forward and backward and were used in the 
analyses. To account for the known difference in measured serum creatinine concentrations 
between the Jaffe method (used in the original model derivation cohort) and the enzymatic 
method (used in the current external validation cohort), a previously described linear 
conversion factor was applied to all of the enzymatic serum creatinine concentrations 
included in this external validation (𝑒𝑛𝑧𝑦𝑚𝑎𝑡𝑖𝑐 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = 1.050 ∗
𝐽𝑎𝑓𝑓𝑒 𝑚𝑒𝑡ℎ𝑜𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 − 0.122).[12] Exclusion criteria included a diagnosis of 
congenital kidney disease, major congenital heart disease (other than ventricular septal 
defect, atrial septal defect, or patent ductus arteriosus), or extracorporeal membrane 
oxygenation (ECMO) during the vancomycin course. 
 
Model Evaluation 
The published neonatal vancomycin population pharmacokinetic model was 
implemented in the non-linear mixed effects modeling software NONMEM 7.2 (ICON 
Development Solutions, Ellicott City, MD) as previously described.[7] Briefly, a one 
compartment model with first-order elimination was used to describe vancomycin 
pharmacokinetics. Clearance (CL) was predicted by weight (an indicator of size), 
postmenstrual age (PMA; an indicator of maturation) and serum creatinine (Cr; an indicator 
of renal function) according to the following equation: 
𝐶𝐿 (𝐿/ℎ) = 0.345 ∙  (
𝑊𝑒𝑖𝑔ℎ𝑡
2.9 𝑘𝑔










Volume of distribution (V) was predicted by weight: 
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After accounting for known predictors, the remaining variation between neonates 
was described by an exponential error model for both CL (% coefficient of variation [% 
CV] 21.6%) and V (% CV 10.9%). Residual variability (a measure of the difference 
between the model predicted concentration for a neonate and the observed concentration 
in that neonate) was captured using a combined proportional (% CV 20.5%) and additive 
error model (standard deviation [SD] ± 1.3 mg/L). 
For each neonate in the external validation cohort, vancomycin concentrations were 
then predicted by using the parameters of the population pharmacokinetic model and 
simulating the actual dosing regimen given to the neonate (using the NONMEM 
MAXEVAL=0 POSTHOC command). Only concentrations at times for which a neonate 
had therapeutic drug monitoring performed were simulated. Model-predicted vancomycin 
concentrations (PRED from the NONMEM output) were then compared with the 
corresponding observed vancomycin concentrations. As described by Sheiner and 
Beal,[13] the bias and precision of the model were assessed by calculating the median 
prediction error and median absolute prediction error for the first trough and peak 
concentration according to the following formulas: 








where Concpred refers to the model-predicted vancomycin concentration and Concobs refers 
to the observed vancomycin concentration. Model predicted vancomycin concentrations 
calculated using each patient’s individual Bayesian estimate of CL and V (i.e. the IPRED 
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from the NONMEM output which incorporates the patient’s drug concentrations in 
addition to the fixed covariate effects in the model predictions) were also evaluated using 
the same approach.  
The predictive performance of the model was further evaluated using simulation-
based diagnostic methods. Normalized prediction distribution errors (NPDE) were 
calculated by simulating 1000 datasets and comparing the predicted concentrations to the 
observed concentrations using the NPDE command in NONMEM.[14, 15] The NPDE 
should follow a normal distribution with a theoretical mean of 0 and variance equal to 
1.[14] 
 
Trough Concentration and AUC24 Relationship 
Following model evaluation, the relationship between trough concentration and 
AUC24 was examined. Bayesian estimates of CL for each neonate from the population 
pharmacokinetic model were used to calculate AUC24 at the time that vancomycin trough 
concentrations were collected.[8] AUC24 was calculated as the daily dose ÷ CL. For a given 
trough concentration, the proportion of neonates with that trough concentration who 
achieved an AUC24 ≥400 was calculated. An AUC24 ≥400 mg*hr/L would predict an 
AUC24/MIC ≥400 for an MIC of ≤1 mg/L. AUC24 calculations, descriptive statistics, and 







External Validation Cohort 
Overall, 243 neonates had vancomycin dose and concentration data available and 
served as the external validation cohort. The median dose was 15.5 mg/kg (interquartile 
range [IQR]:  13.9-19.3) and the median dosing interval was 11.5 hrs (IQR:  8.0-12.5 hrs). 
Demographic and clinical characteristics of the neonates in the external validation cohort 
are shown in Table 4.1. For comparison, demographic and clinical characteristics of the 
neonates in the cohort used to develop the original published pharmacokinetic model are 
also shown. Overall, the validation cohort was of lower weight and age and had higher 
serum creatinine concentrations. 
In the external validation cohort, a total of 734 vancomycin concentrations were 
available for analysis. Each neonate contributed a mean of 3.0 (± 1.8) vancomycin 
concentrations. The time of vancomycin concentration collection relative to the previous 
dose is shown in Table 4.2. All neonates had at least one concentration measured within 
three hours of the end of the vancomycin infusion. No concentrations were below the lower 
limit of quantitation. 
 
Model Evaluation 
The vancomycin pharmacokinetic model adequately described the observed 
vancomycin concentrations in the external cohort of neonates (Figure 4.1A). Model 
predicted vancomycin concentrations (PRED) were slightly lower than the observed 
concentrations (median prediction error -0.8 [95% CI:  -1.4 to -0.4] mg/L). The precision 
of the model was reasonable with a median absolute prediction error of 3.1 (95% CI:  2.7   
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Table 4.1. Demographic and clinical characteristics of neonates who received vancomycin 
and had therapeutic drug monitoring performed. 
Characteristic 
Model Development Cohort 
(n=249) a 
External Validation Cohort 
(n=243) b 
Median / No. Range Median / No. Range 
Female, n (%) 121 (49%) -- 103 (42%) -- 
Gestational 
age, weeks 
34 23 – 42 30 22 – 41 
Birthweight, 
kg 
2.0 0.4 – 4.4 1.3 0.5 – 5.1 
Weight, kg 2.9 0.5 – 6.3 1.6 0.4 – 6.8 
Postnatal age, 
days 
19 0 – 173 12 0 – 196 
Postmenstrual 
age, weeks 
39 24 – 53 33 23 – 54 
APGAR at 5 
minutes 




0.4 0.1 – 2.7 0.6 0.3 – 1.5 
a Patient characteristics of the 249 neonates used to develop the neonatal vancomycin 
population pharmacokinetic model described by Frymoyer et al.[7] 
b Patient characteristics of the 243 neonates used in the current external validation. 
c The serum creatinine concentration in the model derivation cohort was measured 
using the Jaffe method. The serum creatinine concentration in the external validation 
cohort was measured using the enzymatic method and was converted to a Jaffe-
standardized equivalent using a linear equation described by Srivastava et al.[12] 





Table 4.2. Timing of 734 neonatal vancomycin concentrations relative to the end of the 
most recent 1 hour infusion. 
Time since the end of 
the most recent 
infusion 
N (%) 
0 – 1 hr 122 (17%) 
1 – 2 hrs 192 (26%) 
2 – 4 hrs 27 (4%) 
4 – 6 hrs 63 (9%) 
6 – 8 hrs 66 (9%) 
8 – 12 hrs 152 (21%) 
12 – 24 hrs 107 (15%) 





Figure 4.1. An external evaluation of the predictive performance of a previously published 
neonatal vancomycin population pharmacokinetic model. (A) Diagnostic plot depicting the 
model fit for observed versus population-predicted vancomycin concentrations. The 
dashed black line represents the locally weighted scatterplot smoothed fit of the data. (B) 
Kernel density plot of the normalized prediction distribution errors with a histogram 




to 3.2 mg/L). The predictive performance of the model for peak and trough concentrations 
is featured in Table 4.3. When incorporating patient concentrations to obtain Bayesian 
estimates of PK parameters for each neonate, the precision of the model predicted 
vancomycin concentrations (IPRED) improved (Table 4.4).  For example, the median 
absolute prediction error of IPRED was 1.7 (95% CI:  1.5 to 1.8) mg/L. 
Simulation based diagnostics of the vancomycin pharmacokinetic model 
demonstrated a mean NPDE of 0.05 and a variance of 0.96, indicating no bias and an ability 
of the model to reasonably capture the underlying variability in the external validation 
cohort. Additionally, there were no trends in NPDE across weight, postmenstrual age, 
serum creatinine, or time after dose (Figure 4.2). 
 
Trough Concentration and AUC24 Relationship 
A linear relationship between increased AUC24 and higher trough concentrations 
was observed in the external validation cohort (r2 = 0.60; Figure 4.3A). AUC24 was highly 
variable at a given trough concentration (i.e., a 2 to 3 fold range of AUC24 was achieved at 
a given trough concentration), and therefore, AUC24 could not be precisely predicted for 
an individual neonate based on a trough concentration alone. However, a trough 
concentration of 11 mg/L predicted the achievement of an AUC24 ≥400 in 93% of neonates 





Table 4.3. Predictive performance of the neonatal population pharmacokinetic model in 




First peak First trough 
Prediction error 
Median -0.8 -2.0 -0.1 
95% confidence interval -1.4 to -0.4 -2.9 to -1.4 -0.5 to 0.2 
Percent prediction error 
Median -4.5% -7.5% -1.5% 
95% confidence interval -7.2% to -2.2% -9.4% to -4.9% -4.5% to 2.7% 
Absolute prediction error 
Median 3.0 3.9 2.1 
95% confidence interval 2.7 to 3.5 3.4 to 4.1 1.7 to 2.7 
Absolute percent prediction error 
Median 15.2% 12.6% 20.1% 




Table 4.4. Predictive performance of the neonatal population pharmacokinetic model in 
the external validation cohort after incorporating patient drug concentrations in 




First peak First trough 
Prediction error 
Median -0.7 -1.7 -0.2 
95% confidence interval -0.9 to -0.5 -2.2 to -1.4 -0.4 to 0.1 
Percent prediction error 
Median -3.8% -5.8% -1.7% 
95% confidence interval -4.9% to -3.2% -7.5% to -4.6% -3.4% to 0.6% 
Absolute prediction error 
Median 1.7 2.7 0.9 
95% confidence interval 1.5 to 1.8 2.1 to 3.1 0.7 to 1.1 
Absolute percent prediction error 
Median 8.8% 8.4% 9.1% 





Figure 4.2. Assessment of the predictive performance of the neonatal vancomycin 
population pharmacokinetic model. (A) Normalized prediction distribution errors versus 
weight, measured in kilograms. (B) Normalized prediction distribution errors versus the 
time elapsed since the last vancomycin dose, measured in hours. (C) Normalized prediction 
distribution errors versus postmenstrual age, measured in weeks. (D) Normalized 
prediction distribution errors versus serum creatinine concentrations, measured in 
milligrams per deciliter. The dashed black lines represent locally weighted scatterplot 




Figure 4.3. The association between vancomycin trough concentrations and the extent of 
drug exposure, as measured by the 24-hour area under the curve (AUC24). (A) Higher 
vancomycin trough concentrations were associated with higher AUC24 values, although 
substantial variability was noted. (B) The probability of achieving a pharmacokinetic / 
pharmacodynamic target associated with clinical and microbiological success for invasive 
methicillin-resistant Staphylococcus aureus infections (an AUC24 ≥400) increased with 
higher vancomycin trough concentrations. All neonates with a trough ≥12 mg/L had an 





External validation of a population pharmacokinetic model is described by the 
United States Food and Drug Administration (FDA) as “the most stringent method for 
testing a developed model”.[16] Yet, external validation is performed in <10% of published 
pharmacokinetic models and concerns about the clinical utility of the model often 
remain.[17] The external validation performed in the current study strengthens a previously 
published neonatal vancomycin population pharmacokinetic model. Namely, we found the 
pharmacokinetic model to be unbiased across the largest cohort of neonates used in a 
validation study to date. The precision of the model when utilizing only a neonate’s 
postmenstrual age, weight, and serum creatinine was 12.6% for peak concentrations and 
20.1% for trough concentrations.  When a neonate’s drug concentrations are incorporated 
into the model (such as would occur after therapeutic drug monitoring in the NICU), the 
precision further improved to 8.4% and 9.1% for peak and trough concentrations, 
respectively.  This level of precision suggests that the model may be useful in evaluating 
vancomycin dosing regimens and estimating the extent of drug exposure in the clinical 
setting. 
A recent clinical study by Ringenberg et al. highlights the current challenges with 
vancomycin dosing in neonates. In a multicenter retrospective evaluation, vancomycin 
dosing guidelines from Neofax resulted in only 25% of the neonates studied achieving a 
target trough concentration of 10-20 mg/L with empiric dosing.[4] Moreover, the authors 
reported that 20% of the neonates included in their study had a trough concentration <5 
mg/L (Theresa Ringenberg personal communication, April 15, 2015). Even after 
therapeutic drug monitoring and dose-adjustment, only 45% of neonates achieved the goal 
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trough concentration of 10-20 mg/L at any point during their course of therapy. This study 
clearly reveals the significant clinical challenge associated with reliably achieving 
therapeutic and safe vancomycin concentrations in this highly variable patient 
population.[4] More innovative vancomycin dosing strategies and approaches are needed 
in neonates that can help providers personalize empiric dose selection, interpret therapeutic 
drug monitoring data, and adjust dosing so that exposure targets are achieved.  
Population pharmacokinetic models are a powerful tool that can aid clinicians and 
help inform dosing decisions.[18, 19] By incorporating patient-specific characteristics, 
dosing information, drug concentrations, and consideration of the variability between 
patients, population pharmacokinetic models offer the opportunity to provide a more 
personalized approach to therapeutic decision making. This is especially valuable in a 
highly variable population, such as neonates, receiving a narrow therapeutic window drug 
such as vancomycin.  
In adults, Bayesian approaches utilizing population pharmacokinetic models have 
already been shown to have the potential to help support vancomycin dosing decisions.[19, 
20] Advancement of similar approaches in neonates is needed. The development and 
external validation of a neonatal vancomycin population pharmacokinetic model lays the 
foundation for this future work. For example, our group is currently developing a model-
based approach to individualize the empiric dose in neonates that incorporates the 
predictors of weight, postmenstrual age, and serum creatinine. Using a simulation 
framework, the vancomycin dose for a given neonate that is most likely to achieve an 
AUC24 >400 while still maintaining a trough concentration <20 mg/L is calculated. A user-
friendly, web-based application is currently being developed to facilitate the adoption of 
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this model in our neonatal intensive care units, including integration into the electronic 
health record.  In addition, the ability to estimate AUC24 and assist providers with dose 
adjustment within the clinical workflow would be of high value.  
Until more robust clinical dosing support tools are developed, clinicians will 
continue to rely on trough concentration monitoring to help guide vancomycin dosing in 
neonates. Our findings reinforce the large variability observed in vancomycin trough 
concentrations among neonates and the inability of a trough concentration alone to reliably 
predict an individual neonate’s AUC24.  Targeting an AUC24/MIC ≥400 is recommended 
by the Infectious Disease Society of America when treating invasive MRSA infections, 
and a trough concentration of 15-20 mg/L is suggested in adults to achieve this target.[1, 
21] The current study provides further support that in neonates a vancomycin trough 
concentration of 15-20 mg/L is unnecessary to achieve an AUC24/MIC ≥400 with an MIC 
≤1 mg/L and that lower trough concentrations are likely adequate based on AUC24 
considerations.[7] Accordingly, a trough concentration of approximately 10 mg/L is likely 
a reasonable first-line target that will provide adequate exposure for invasive MRSA while 
also appropriately covering for coagulase negative staphylococcal infections.  Further dose 
adjustment and individualization of the therapeutic approach should be guided by the 
specific pathogen identified, susceptibility testing, clinical status, etc. For example, for 
MRSA infections with MICs ≥2 mg/L, an alternative to vancomycin may be necessary 
since an AUC24/MIC ≥400 will not be achieved in neonates even at trough concentrations 
of 15-20 mg/L.[7] Lastly, the extent to which the target AUC24/MIC ≥400 is generalizable 





In summary, an evaluation of a recently published neonatal vancomycin population 
pharmacokinetic model in a large external dataset supported the predictive performance 
and generalizability of the model. The model may be useful in evaluating vancomycin 
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PRELIMINARY ASSESSMENT OF ZOLPIDEM 




 Purpose: Severely burned patients frequently experience sleep fragmentation and 
insomnia. This study evaluated the population pharmacokinetics of the sleep-enhancing 
agent zolpidem among burned children. 
Methods: Zolpidem was administered according to the following age-based dosing 
schedule: 2-4 years, 2.5 mg/dose; 5-10 years, 5.0 mg/dose; and >10 years, 10 mg/dose. 
Serum samples were collected pre-dose, 1, 2, 4, 5, 6, and 8 hours post-dose. The population 
pharmacokinetic analysis modelled zolpidem concentrations using non-linear mixed 
effects models. 
Results: Eleven patients with a mean (+SD) age of 8.3+4.0 years and a mean total 




measured with a mean Cmax of 291+140 ng/mL. A two-compartment model with first-order 
absorption best described the data. Zolpidem clearance was estimated at 0.03 L/hr/kg 
(relative standard error, 55%) and increased with body weight (P<0.05). The central 
compartment volume of distribution was estimated at 0.05 L/kg (relative standard error, 
25%), which was inversely related to the proportion of the body surface with third degree 
burns (P<0.001). 
Conclusions: A population pharmacokinetic model has been developed that reliably 
characterized the pharmacokinetic parameters of zolpidem when used as a sleep-enhancing 
agent among pediatric burn patients. Further studies are needed to link this 
pharmacokinetic model with pharmacodynamic data, which may include an assessment of 




Zolpidem tartrate is an imidazopyridine sedative and hypnotic agent that is rapidly 
absorbed, metabolized, and eliminated.[1] In studies among adult subjects, zolpidem has 
been shown to decrease the number of night-time awakenings, decrease the time required 
to fall asleep, increase total sleep time, and improve sleep quality among insomniacs.[2] 
Zolpidem has been used for the management of sleep disorders for more than 20 years and 
has been reported to be safe and effective for a variety of sleep-related complaints.[3, 4] 
Burn injuries are marked by a dramatic catabolic phase that is characterized by an 
increase in energy expenditure, protein catabolism, and cachexia.[5, 6] Alterations in sleep 
patterns have been shown to be independent risk factors for poor pain tolerance in adults 
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with severe burn injuries.[7] Among burn patients, restorative sleep may be impaired due 
to physiological, psychological, environmental, and treatment-related stimuli that interfere 
with normal sleep patterns.[8-10] These detrimental effects suggest that sleep-enhancing 
agents, such as zolpidem, may be useful for improving burn survival and recovery.[11] 
In a recent study, children with severe burn injuries were randomized to receive 
zolpidem or haloperidol and had continuous polysomnographic recordings obtained to 
evaluate the effects of these agents on sleep architecture.[12] Forty patients were enrolled 
in this blinded crossover study, in which each patient alternately received zolpidem one 
week and haloperidol the next. Zolpidem was found to have a small, but significant, effect 
in improving the proportion of stage 3 and rapid eye movement sleep (0.8 vs. 0.6 hours), 
but did not affect the total duration of sleep. In contrast, haloperidol increased total sleep 
time (5.3 vs. 4.3 hours) and increased stage 2 sleep (3.3 vs. 2.4 hours). The authors 
concluded that sleep was marginally improved with both drugs and there were no 
significant differences between the two therapeutic agents. It was noted, however, that the 
relatively short half-life of zolpidem (mean 2.5 hours) may have attenuated its beneficial 
effects upon sleep architecture. To date, no studies have examined zolpidem 
pharmacokinetics in burn patients; however, drug metabolism is generally thought to be 
elevated as a consequence of the pathophysiology of burn injuries, including: altered 
protein binding, bioavailability, and tissue blood flow; heightened renal clearance; and a 
higher volume of distribution.[13, 14] As a consequence of these pharmacokinetic changes 
and the relatively short half-life of zolpidem, it is possible that this agent may fail to prevent 
sleep fragmentation as it wears off, thereby decreasing the amount of restorative sleep 
among burn patients. 
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The primary aim of this study was to develop a population pharmacokinetic model 
to explore the pharmacokinetics of zolpidem among children with severe burn injuries. 
 
Materials and Methods 
Subjects and Study Design 
This study was conducted as an open-label inpatient pharmacokinetic study that 
involved pediatric burn patients who consented to receive zolpidem tartrate for use as a 
sleep-enhancing agent over four consecutive days. Acutely burned children were screened 
at the time of their admission to the burn unit for enrollment into this prospective 
pharmacokinetic study. Inclusion criteria included a total burn surface area (TBSA) greater 
than 20%, age between 3 and 18 years, and admission within 5 days of the burn injury. 
Children were excluded from enrollment if there were pre-existing neurological, sleep or 
psychiatric disorders; a history of brain injury; endocrine disease; questionable 72 hour 
survival; severe obesity (body mass index >97th percentile); or if administration of other 
sleep-inducing agents was planned within 24 hours. Demographic data were collected for 
all study participants. 
This study was reviewed and approved by the University of Cincinnati Institutional 
Review Board. Parental permission and informed assent (when appropriate) were obtained 
prior to the performance of any study-related procedures. 
 
Drug Administration 
Historically, zolpidem dosing was based upon the age of the child.  In this study, 
we aimed to examine the pharmacokinetics of zolpidem when dosed according to routine 
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clinical practice. Dose amounts for each child are presented in Table 5.1. Two pilot subjects 
received a single 5 mg night-time dose of zolpidem at 2200 hours. Nine subsequent patients 
received a second dose at 0200 hours in an attempt to maintain sleep throughout the night. 
Zolpidem was administered as a crushed tablet that was dissolved in 5 mL of water and 
was given via a nasoenteric Frederick-Miller feeding tube, followed by a 5 mL flush.  
 
Sample Collection 
Zolpidem concentration-time data were prospectively collected for each enrolled 
subject. On the fourth and final day of zolpidem therapy, blood samples were collected 
over an 8-hour period from an indwelling catheter. Samples were drawn in non-heparinized 
tubes immediately prior to the first dose and at 1, 2, 4, 5, 6, and 8 hours post-dose. The 
total amount of blood drawn at each sampling interval did not exceed 3.0 mL. Whole blood 
samples were centrifuged at 1500 g (approximately 3000 rev/min) for 10 min at 4°C. 
Centrifuged samples were then stored at -80°C prior to pharmacokinetic analysis. 
 
Analytical Assay 
Zolpidem serum concentrations were analyzed using a validated high-performance 
liquid chromatography (HPLC) assay tethered to a fluorescence detector.[15] The assay 
was linear over the range from 25-1000 ng/mL. Intra- and inter-day coefficients of 










































































































































































































































































































































































































































































































































































Zolpidem pharmacokinetic parameters were estimated using Monolix 4.2 (Lixoft, 
Orsay, France), interfaced through Matlab R2012b (The Mathworks Inc., Natick, MA, 
United States). Monolix employs a stochastic approximation expectation maximization 
parameters without approximating the statistical model.[16] The consistency and minimum 
variance of the estimates have been optimized in the Monolix SAEM implementation.[17] 
Furthermore, Markov Chain Monte Carlo (MCMC) simulations were performed in 
Monolix using a simulated annealing procedure to accelerate the algorithm’s convergence 
toward a solution. Descriptive statistics were used to characterize the study population with 
Stata 11.2 (StataCorp, College Station, TX, United States) and R version 2.15.1 (Cran.R-
project.org). 
One- and two-compartment structural models were fitted to the naïve pooled data 
with and without lags. All compartmental models were parameterized to give estimates of 
zolpidem clearance (CL/F) and the apparent volume of distribution (Vd/F). Models were 
evaluated and selected based on the goodness of fit. Unstable models were excluded from 
the model building process, as well as models that produced non-physiological results (e.g., 
negative clearance). Model stability was assessed by changing the initial estimates for CL/F 
and Vd/F. 
Selection of structural models was facilitated using the Akaike information 
criterion (AIC) and the Bayesian information criterion (BIC).[18] During model 
development several diagnostic plots were used to visually assess the model’s fit, including 
observed versus population predicted zolpidem concentrations and observed versus 
individual predicted zolpidem concentrations. Plots of the residuals and conditional 
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weighted residuals (CWRES) versus time or population predicted zolpidem concentrations 
were also visually inspected. Models were also compared by examining the precision of 
parameter estimates, measures of variability, and the objective function value (OFV). 
Model fit was based on minimization of the OFV. A reduction of more than 3.84 (-2 log 
likelihood difference) was considered statistically significant with P<0.05 and one degree 
of freedom. 
A mixed effects model was built to incorporate intra- and inter-individual 
variability and residual unexplained variability (RUV). Inter-individual variability was 
assumed to be log-normally distributed and was assessed using an exponential equation of 
the form:  
𝐶𝐿𝑖/𝐹 = 𝜃𝑝𝑜𝑝 ∗ exp⁡(𝜂𝑖) 
(5.1) 
where CLi/F is the clearance value parameter for the ith individual, θpop is the population 
mean for zolpidem CL, and η represents the inter-individual random effect with a mean of 
zero and a variance of ω2. 
During model development, RUV was evaluated using a combined additive and 
constant coefficient of variation error model. This followed the form of: 
Y = IPRED ∗ (1 + 𝜀prop) + 𝜀add (5.2) 
where Y is the observed zolpidem concentration, IPRED is the individual predicted 






Base Model Development 
The base model was developed using an empirical approach that focused on 
assessing several structural models. An evaluation of multiple absorption models was 
performed to identify the model that best described zolpidem absorption in the dataset. Lag 
time and absorption rate constants (Ka) were also assessed to determine if they improved 
estimations of the zolpidem absorption process. 
 
Covariate Analysis 
Several demographic and clinical characteristics were investigated for their 
influence upon zolpidem pharmacokinetics. Patient age, gender, race, ethnicity, type and 
extent of burn injury, elapsed time since the burn injury, current body weight, height, and 
body mass index (BMI), C-reactive protein (CRP), and serum creatinine were evaluated. 
An exploratory analysis was performed to identify relationships between zolpidem 
pharmacokinetic parameters and the above characteristics. The empirical Bayesian 
estimates from the individual parameters obtained from the base model were plotted 
against the covariate values and were compared by visual inspection. 
To correct for differences in body size and metabolic rate, allometric scaling was 
applied to zolpidem CL/F and Vd/F, which were standardized to a body weight of 70 
kg.[19] After the initial analysis, final covariates were selected for inclusion within the 
model following a stepwise inclusion approach. Covariates were added within the model 
until there was no further decrease in the OFV. A backward stepwise approach was used 





Model performance was assessed numerically and graphically, in which observed 
drug concentrations were visually inspected for their correlation with predicted 
concentrations. As described by Goobie et al., conditional weighted residual plots were 
constructed and assessed using the empirical -2 to +2 region criterion, in the absence of 
any serial correlation or heteroscedasticity.[20] Standard errors were assessed for both the 
estimated population parameters and random effects error models. Goodness-of-fit plots 
and visual predictive checks were used to evaluate model fit. The final covariate model 
was also assessed by generating numeric and visual predictive checks. Further, the final 
model was also assessed with plots of the normalized prediction distribution error (NPDE) 
as a function of time and population predicted zolpidem concentrations.[21] 
 
Results 
Subjects and Pharmacokinetics 
Data were collected from 11 children with acute burn injuries, 8 of whom were 
male and 3 were female. The mean age of the subjects included in this study was 8.3 + 4.0 
years. Additional demographic characteristics of the study cohort are featured in Table 5.1. 
The extent of the mean TBSA burn was 56% + 22%. All 11 children had thermal burn 
injuries and 2 (18%) patients also suffered an inhalation injury. 
Two pilot subjects received a single dose of zolpidem just prior to sleep onset 
(10:00 p.m.). Nine subjects also received a second dose of zolpidem 4 hours after the first 
dose (2:00 a.m.). There were 73 zolpidem serum concentrations measured with a median 
of 7 (range 5-7) per patient. 
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Initial exploratory analysis of the data revealed characteristic concentration-time 
profiles for all subjects. Figure 5.1A displays the raw zolpidem concentration data at each 
sample time for the two pilot patients who received a single dose of zolpidem. Figure 5.1B 
presents the raw zolpidem concentration data for the subsequent nine patients who received 
two doses. For these patients, the mean peak serum concentration was 291 + 140 ng/mL. 
 
Population Pharmacokinetic Models 
The population pharmacokinetic analysis included all 73 measured zolpidem 
concentrations from the 11 study participants. A two-compartment model with first order 
absorption was identified as the base model that best described the data, as assessed by the 
OFV, AIC, and BIC. This model was utilized for subsequent covariate model development. 
 
Covariate Models 
Inclusion of body weight in the initial covariate analysis revealed that 
allometrically-scaled body weight exerted a substantial influence upon zolpidem CL/F. 
Additionally, the volume of distribution in the central compartment (Vc/F) was inversely 
associated with the proportion of the body surface with third degree burns. None of the 
other covariates (e.g., age, gender, race, ethnicity, type of burn injury, total body burn 
surface area, elapsed time since the burn injury, CRP, and serum creatinine) influenced 
zolpidem pharmacokinetic parameter estimates. 
The final covariate model was selected as it produced the most significant reduction 
of the OFV (Δ 13.5), reduced the inter-individual variability, and decreased the RUV. 




Figure 5.1. Zolpidem concentration versus time curves. (A) Two pilot subjects received a 
single dose of zolpidem and (B) nine subjects received an additional dose of zolpidem four 
hours after receiving their first dose.  
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the final model (Figure 5.2). The parameter estimates derived from the final covariate 
model are featured in Table 5.2. 
 
Model Evaluation 
Diagnostic plots of the population and individually predicted zolpidem 
concentrations were compared against the observed concentrations for all patients (Figure 
5.2). Conditional weighted residuals and NPDE metrics revealed a random distribution 
around 0, with nearly all values within the -2 to +2 range (Figure 5.3). Simulations from 
the observed zolpidem concentration data are presented in Figure 5.4 using a visual 
predictive check, with the median value compared to the 10th and 90th percentiles. 
Approximately 94% of the simulated observations fell within the 90% prediction interval, 




This is the first study to evaluate the pharmacokinetics of zolpidem when used as a 
sleep-enhancing agent among children with severe burn injuries. Zolpidem 
pharmacokinetics are strongly influenced by both body weight and the extent of third 
degree burn injuries. Due to the relatively short half-life of zolpidem, a single dose failed 
to result in sleep that persisted throughout the night for two pilot subjects. The remaining 
nine participants received a second dose administered 4 hours later, which improved the 




Figure 5.2. Zolpidem final covariate model observed versus (A) population-predicted 
concentrations and (B) individual-predicted concentrations. The line of identity is shown 




Table 5.2. Zolpidem population pharmacokinetic parameter estimates from the final two-








Θ – Pharmacokinetic Parameters    
Ka - Absorption rate (hr-1) 0.18 (fixed) -- -- 
CL/F - Clearance (L/hr/kg) 0.03 0.015 55 
Vc/F 
- Volume of distribution in the 
central compartment (L/kg) 
0.05 0.012 25 
Q/F 
- Intercompartmental clearance 
(L/hr/kg) 
0.04 0.020 47 
Vp/F 
- Volume of distribution in the 
peripheral compartment (L/kg) 
0.69 2.9 421 
ω – Between-Subject Variability    
CL/F - Clearance 0.25 0.26 103 
Vc/F 
- Volume of distribution in the 
central compartment 
0.37 0.09 26 
Q/F - Intercompartmental clearance 0.96 0.28 30 
Vp/F 
- Volume of distribution in the 
peripheral compartment 
4.3 3.2 75 





Figure 5.3. Zolpidem final covariate model (A) conditional weighted residuals versus time 
and population-predicted concentrations and (B) normalized prediction distribution errors 
























































































Few studies have established therapeutic dosage regimens for sleep-enhancing 
agents among children.[22] The only other pediatric zolpidem pharmacokinetic study was 
conducted by Blumer et al., which utilised a single dose escalation design to evaluate three 
zolpidem dosage regimens (0.125, 0.25, and 0.5 mg/kg) among otherwise healthy children 
with insomnia.[23] The authors found that zolpidem doses of >0.25 mg/kg (maximum of 
10 mg/day) were safe, well tolerated, and potentially efficacious. However, the 
appropriateness of this dosing regimen for children with severe burn injuries is unknown. 
Burn injuries evolve over time and can profoundly impact the pharmacokinetics and 
pharmacodynamics of many drugs.[24] A few days after the burn injury, patients enter a 
hypermetabolic state with high blood flow to the liver and kidneys, increased α1-acid-
glycoprotein concentrations, and loss of the drug due to exudate leakage – all of which 
contribute to altered protein binding, drug distribution, and clearance.[25] Clinically, many 
hypermetabolic burn patients eliminate drugs rapidly, necessitating higher doses and/or 
shorter dosing intervals to maintain therapeutic serum concentrations. In a previous study, 
we evaluated the effects of a single zolpidem dose of 0.5 mg/kg upon sleep duration and 
architecture among burned children.[12] The authors found that this dose was ineffective 
in restoring normal sleep architecture and speculated that sleep fragmentation may have 
occurred later in the night as a consequence of sub-therapeutic serum concentrations. 
Further pharmacodynamic assessments are needed to assess whether a second dose 
administered 4 hours after the first improves sleep quality in this critically-ill pediatric 
population. 
In the previously mentioned study conducted by Blumer et al., the 
pharmacokinetics of zolpidem were evaluated among otherwise healthy children suffering 
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from insomnia.[23] Age was found to significantly influence the zolpidem area under the 
concentration time curve, half-life, and mean residence time. In this study, body weight 
was significantly associated with zolpidem clearance, which likely reflects the cachexia 
associated with severe burn injuries. Additionally, the extent of third degree burn injuries 
was inversely associated with the volume of distribution in the central compartment. As a 
consequence, the children enrolled in this study achieved higher serum zolpidem 
concentrations than have been previously reported among healthy children.[23] This may 
be at least partially attributable to pathophysiologic changes in the volume of distribution 
among burn patients, which strongly affect hydrophilic drugs such as zolpidem tartrate.[26] 
Despite the relatively high zolpidem concentrations measured in this study, it was noted by 
clinical investigators that with two doses each night sleep quantity and quality were still 
suboptimal. Future studies are warranted to define the relationship between the sleep-
enhancing effects of zolpidem (pharmacodynamics) and measured serum concentrations. 
Defining this relationship will be critical to ensure that a therapeutic range is developed for 
children with severe burn injuries.  
Recently, the U.S. Food and Drug Administration (FDA) approved new labelling 
changes, which advocate a lowering of the recommended initial dose of immediate- and 
extended-release zolpidem formulations.[27, 28] These changes were made to decrease the 
risk of next-day driving impairment among adults; however, the appropriateness of this 
recommendation for pediatric patients is not known. In this study, two pilot subjects who 
received a single 5 mg dose of zolpidem failed to sustain sleep throughout the night. The 
next nine subjects received a second dose of zolpidem during the latter half of the night, 
which was found to improve sleep duration. According to recent FDA guidelines,[27] the 
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recommended initial dose of the immediate-release formulation of zolpidem is now 5 mg 
for women and 5 or 10 mg for men. The gender-specific difference in dosing 
recommendations is a function of adult pharmacokinetic studies conducted among healthy 
volunteers, which reported that women clear zolpidem at a slower rate than men.[29] Sex 
was not identified as a significant covariate in this pediatric burns study; however, the 
limited sample size may have obscured our ability to detect a subtle variation in zolpidem 
clearance between male and female participants. 
Interpretation of these findings warrants the consideration of several limitations. 
First, the association between zolpidem pharmacokinetics and pharmacodynamic 
endpoints, including changes in sleep architecture, remains unknown for pediatric burn 
patients. Further research is needed to link zolpidem dosing with polysomnographic 
evidence of clinical efficacy. Second, children in this study were enrolled at a mean of 18 
days post-burn. As such, the findings described herein may not generalize to children in 
the hypermetabolic stage immediately following their burn injury nor after significant 
wound healing and convalescence has occurred. Third, this study featured a limited number 
of serum samples from eleven children with severe burn injuries. This relatively small 
sample size limits our ability to precisely define the covariates that influence the disposition 
of zolpidem tartrate; however, this is the first study to date that has sought to systematically 
evaluate the pharmacokinetics of this drug in this unique patient population. Lastly, 
inadequate pain control in the burn population has been associated with poor sleep 
quality.[8] In this study, it was not possible to correlate pain control with sleep 





The current study characterized the pharmacokinetic parameters of zolpidem when 
used as a sleep-enhancing agent among children with severe burn injuries. Assessments 
from the clinical team treating the first two pilot subjects suggested that a single 5 mg dose 
of zolpidem was insufficient to achieve sustained sleep throughout the night. Nine 
subsequent patients received a second dose 4 hours after the first, which increased the 
duration of sleep through the latter half of the night. These findings suggest that future 
clinical trials should investigate higher doses and/or more frequent dosing for children with 
acute burn injuries. Recent FDA recommendations to decrease adult zolpidem doses are 
not likely to be appropriate for severely burned children. Further studies are needed to 
define the target zolpidem concentration required to improve sleep architecture among 
burned children. Additionally, pharmacodynamic studies and simulations may be helpful 
in developing appropriate dosing regimens for this vulnerable population. 
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CHAPTER 6 
 
SIMULATION-BASED PHARMACOMETRIC  
BENCHMARKING OF MONOLIX,  
NONMEM, AND PMETRICS 
 
Introduction 
Pharmacometric models can be used to quantify the variability in drug 
concentrations over time by fitting mathematical equations to clinical data. Population 
pharmacokinetic analyses involve the fitting of nonlinear mixed effects models to dosing 
and concentration data from multiple subjects at multiple points in time.[1-4] Mixed effects 
modeling involves the simultaneous quantification of the effects of random variability 
(between subject and residual variability) and fixed effects (such as weight, age, or renal 
function) on plasma drug concentrations.[5] These models are useful in then defining 
influential sources and correlates of variability in drug concentrations among patients, 
which can be used to derive personalized dosing regimens.[6] 
Multiple software platforms have emerged over the last 30 years for conducting 
population pharmacokinetic analyses, many of which feature different parameter 
estimation methods that have the potential to lead to different results when the same 
structural model is fit to the same dataset.[2, 3] For this reason, benchmarks are needed to
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experimentally assess the strengths and weaknesses of current pharmacometric modeling 
programs and their estimation methods. The accuracy and precision of these 
pharmacokinetic parameter estimates may impact clinical decisions and lead to alterations 
in medical management, such that the selection of a pharmacokinetic parameter estimation 
method with lower bias and higher precision is desirable. Additionally, it is unknown 
whether the selection of the optimal modeling program and parameter estimation method 
differs based on the design of the clinical trial. The objective of this study was to assess the 
predictive performance of three of the most commonly used population pharmacokinetic 
modeling programs and their parameter estimation algorithms when applied to simulated 
data under a variety of clinical trial designs with varying amounts of error, varying sample 




 This study was designed to assess the predictive performance of three commonly 
used population pharmacokinetic modeling programs when their respective 
pharmacokinetic parameter estimation algorithms were applied to simulated datasets. 
Construction of the simulated one compartment datasets was performed using a structural 
model of the form: 
One-compartment model:  𝑑𝐴1
𝑑𝑡
= −𝑘𝑒𝑙 ∗ 𝐴1 (6.1) 
Initially, a dataset was simulated with 160 neonatal subjects, each of whom received a 
single 140 mg/kg dose of the drug and had a total of 10 plasma concentrations measured at 
5, 15, 30, 45, 60, 90, 120, 180, 360, and 540 minutes post-dose. 
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To assess the impact of varying the amount of error on the predictive performance 
of each software program, new datasets were constructed in which each concentration was 
randomly permuted by 20%, 40%, 60%, and 80%. Additionally, to assess the influence of 
the study design parameters on the predictive performance of the software programs, the 
number of subjects (n = 10, 20, 40, 80, and 160) and the number of concentrations obtained 
from each subject (n = 2, 4, 6, 8, and 10) was varied. These permutations of the original 
simulated dataset resulted in the generation of 100 datasets due to the creation of unique 
datasets with each combination of the error, sample size, and number of concentration 
terms (4 error terms * 5 sample size terms * 5 concentration number terms = 100 unique 
datasets). A survey of the literature was performed to confirm the sample size, number of 
concentrations per subject, and error terms included in the simulations covered a sufficient 
range of values that may be reasonably expected to be feasible when designing a 
prospective clinical trial.[6-8] These datasets are included in Appendix C. 
The 100 simulated datasets were generated by MGS and CMTS and were labeled 
with coded identifiers, such that the investigator performing the analysis (CS) was blinded 
to the true values used to initialize the simulation and to the amount of error included in 
each dataset. 
 
Software Programs Tested 
 Three population pharmacokinetic modeling programs were employed in this 
benchmarking study.  Each of these software programs allows the user the opportunity to 
employ different estimation algorithms, which are discussed separately in the following 
paragraphs: 
1) Monolix (Lixoft, Orsay, France):  Monolix uses expectation maximization (EM) 
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methods to integrate the posterior density by performing Monte Carlo sampling 
over all possible individual parameters during the expectation step, followed by a 
single iteration maximization step that moves the fixed-effect parameter values 
closer toward the maximum likelihood.[9, 10] Monte Carlo-based methods have 
the advantage of not using a linearized approximation to the integral and are 
theoretically less biased.[9] EM algorithms are inherently stochastic and are 
therefore less likely to be forced into a local minimum but they may yield less 
precise results.[11] 
2) NONMEM (nonlinear mixed effects modelling; ICON Development Solutions, 
Ellicott City, MD, USA):  NONMEM uses the Broyden-Fletcher-Goldfarb-Shanno 
(BFGS) quasi-Newton algorithm to maximize the approximated likelihood.[12] 
With the first-order conditional estimation with interaction (FOCEI) method, the 
likelihood is linearized with respect to the random effects using a first-order Taylor 
series expansion.[2] The integration step is performed by assuming that the 
posterior density can be approximated by a multivariate normal density with respect 
to the individual parameters.[2] 
3) Pmetrics (Laboratory of Applied Pharmacokinetics and Bioinformatics, University 
of Southern California, Los Angeles, CA, USA):  Pmetrics uses a nonparametric 
adaptive grid (NPAG) algorithm to estimate the unknown probability distribution 
(F) of the pharmacokinetic model parameter values using a set of discrete 
distributions with the same number of support points as the number of subjects 
included in the study.[13] To define F, a large grid of potential support points (G0) 
is laid out on the surface of F. To determine probabilities of the support points and 
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the corresponding likelihood, a primal-dual interior point method is used.[14, 15] 
The vast majority of the support points have exceedingly low probabilities (<10-12), 
which are then deleted from the grid yielding a smaller grid (G1). New support 
points are then added around each of the remaining support points, which leads to 
a new expanded grid (G2) with an improved likelihood. This process is iteratively 
repeated thereby giving rise to Gk grids with larger likelihoods. When the difference 
between the previous grid and the current grid is extremely small, the model is said 
to have converged. 
  
Model Implementation 
 The simulated datasets featured a strong influence of weight (kg) on the 
pharmacokinetic parameters of clearance and volume of distribution. As an additional 
sensitivity analysis, the parameter estimates obtained from the three population 
pharmacokinetic modeling programs were compared using incorrectly-specified one-
compartment models that did not account for the influence of weight on clearance or the 
volume of distribution. Correctly-specified models that incorporate the influence of weight 
on clearance and the volume of distribution were also tested to assess the sensitivity of 
these software programs to model misspecification. The influence of weight on clearance 
and the volume of distribution was modeled with an estimated power function of the form: 
𝜃𝑖 = 𝜃𝑝𝑜𝑝 ∗ 𝑊𝑇𝑖
𝜃𝑐𝑜𝑣 ∗ 𝑒𝜂𝑖 (6.2) 
where θi is the individual model-predicted pharmacokinetic parameter (e.g., clearance or 
volume of distribution) for individual i with a weight of WTi (kg), θpop is the population 
mean pharmacokinetic parameter θ, θcov is the effect of the weight covariate, and ηi is the 
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between-subject random effect on the pharmacokinetic parameter θ with a mean of 0 and 
a variance of Ω. The initial estimates for the fixed effects in each model script were 
uniformly set equal to 1. 
A proportional error model was used to describe the residual variability, which took 
the form: 
𝑌𝑖𝑗 = ?̂?𝑖𝑗 + (?̂?𝑖𝑗 ∗ 𝜀𝑖𝑗) (6.3) 
where Yij is the measured drug concentration for the ith individual at time j, Ŷij is the model-
predicted drug concentration, and εij is a normally-distributed random error term with a 
mean of 0 and a variance of Σ. 
 
Statistical Analysis 
The predictive performance of Monolix, NONMEM, and Pmetrics’ respective 
pharmacokinetic parameter estimation algorithms was compared with the true clearance 
and volume of distribution values used to develop the simulated one-compartment 
pharmacokinetic datasets. As described by Sheiner and Beal,[16] the performance of each 
algorithm was assessed by computing its relative bias and precision according to the 
following equations: 
Percent prediction error (bias):                                 100 ∗ (𝜃𝑒𝑠𝑡−𝜃𝑡𝑟𝑢𝑒
𝜃𝑡𝑟𝑢𝑒
) (6.4) 




The bias and precision were calculated for both clearance and the volume of 
distribution estimates derived from each of the population pharmacokinetic modeling 
programs. Analyses were performed globally with the results of all of the datasets pooled 
together, which were then followed by sub-analyses that were stratified by the error, sample 
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size, and number of concentrations per subject terms. Descriptive statistics were calculated 
and the bias and precision were compared for each of the population pharmacokinetic 
modeling programs using the nonparametric Wilcoxon-Mann-Whitney test. All statistical 
analyses were performed in R 3.1.3 (R Foundation for Statistical Computing, Vienna, 
Austria) with a two-tailed alpha of 0.05. 
 
Results 
 Across the 100 datasets, there were a total of 37,200 simulated concentrations. The 
simulated concentration-time profiles for these simulated neonatal subjects are featured in 
Figure 6.1. The median postmenstrual age of the simulated study population was 38.0 
(interquartile range [IQR]:  37.1-39.0) weeks and the median current body weight was 2.17 
(IQR:  1.23-3.42) kg. 
 
Correctly-Specified Models with Covariates 
 The median parameter estimates and the IQR of the parameter estimates for all 
estimated parameters for the correctly-specified models that incorporated the influence of 
current body weight on clearance and the volume of distribution are featured in Figures 
6.2A and 6.2B, respectively, for each of the population pharmacokinetic modeling 
programs. In this figure, the values of the parameters were normalized by dividing the 
model-estimated parameter value by the known, true value. The solid gray horizontal line 
corresponds to the true value of each pharmacokinetic parameter. The x-axis features each 
of the three population pharmacokinetic modeling programs that were tested. The heavy 
solid black horizontal line within each box plot denotes the median normalized value of 
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Figure 6.1. Simulated drug concentration vs. time profiles. A total of 37,200 concentrations 
were simulated across 100 datasets with varying sample sizes, varying numbers of 
concentrations obtained from each subject, and varying error terms. The solid blue line 
depicts the loess spline of the data and the blue shaded region depicts the 95% confidence 
interval for the loess spline.  The vertical gray error bars represent 95% confidence intervals 




Figure 6.2. Clearance (A) and volume of distribution (B) parameter estimates using 
correctly-specified covariate models. For each parameter, the estimated value was 
normalized by the true value. The gray horizontal line depicts the true normalized values 
(equal to 1). The box plots depict the 25th, 50th, and 75th percentiles. The vertical lines 
extending from each boxplot extend to 1.5 times the interquartile range, with values beyond 
this point denoted by unfilled circles. 
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the pharmacokinetic parameters and the lighter weight solid black lines forming the box 
denote the 25th and 75th percentiles. The whiskers extending from each box plot extend to 
1.5 times the IQR. Observations beyond the whiskers are presented as unfilled circles. 
Generally, clearance estimates were biased slightly higher than their true values with both 
Monolix and NONMEM, whereas the volume of distribution estimates were very close to 
their true values with both of these programs. In contrast, clearance estimates were 
generally unbiased with Pmetrics, whereas volume of distribution estimates were biased 
slightly lower than their true values. Notably, the range of normalized values was 
considerably larger for Pmetrics than Monolix, which was in turn slightly larger than that 
observed with NONMEM. 
The bias of the population pharmacokinetic modeling programs was tested with a 
20% error applied to the pharmacokinetic parameters with varying sample sizes and 
numbers of concentrations from each subject. For all three programs, bias decreased with 
larger numbers of concentrations from each subject (P<0.001) and larger sample sizes 
(P=0.005). However, the pharmacokinetic parameter estimates were biased for all three 
population pharmacokinetic modeling programs. As seen in Table 6.1, pharmacokinetic 
parameter estimates obtained from both Monolix and NONMEM were positively biased, 
whereas the estimates obtained from Pmetrics were negatively biased. Monolix was less 
biased than NONMEM, which was less biased than Pmetrics (P<0.001 for all 
comparisons). 
The precision of the population pharmacokinetic parameters was tested with 20% 
error (Figure 6.3A and Table 6.1).  In simulations with larger numbers of concentrations 
from each subject, the percent absolute prediction error decreased with Monolix,  
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Table 6.1. Bias and precision of the estimated population pharmacokinetic parameter 
values obtained using Monolix, NONMEM, and Pmetrics for the correctly-specified 
models with covariates. 
 Monolix NONMEM Pmetrics 





(-1.1% to 64.4%) 
19.1% 
(0.0% to 67.5%) 
-27.8% 





(3.8% to 65.5%) 
21.5% 
(0.5% to 67.5%) 
37.3% 
(22.7% to 60.7%) 





(-1.7% to 62.8%) 
22.7% 
(0.1% to 67.8%) 
-33.1% 





(5.7% to 64.2%) 
22.8% 
(0.9% to 67.8%) 
40.5% 
(26.7% to 63.3%) 





(-2.4% to 61.4%) 
26.1% 
(0.5% to 66.9%) 
-32.9% 





(7.1% to 63.5%) 
26.1% 
(0.9% to 66.9%) 
41.8% 
(26.7% to 62.8%) 





(-3.6% to 60.8%) 
20.9% 
(-0.5% to 66.2%) 
-43.2% 





(8.2% to 62.5%) 
26.6% 
(1.9% to 66.2%) 
49.6% 
(30.9% to 63.6%) 
a Percent prediction error is a measure of bias. 




NONMEM, and Pmetrics (P<0.001). In contrast, increasing sample sizes had a negligible 
effect on percent absolute prediction errors (P=0.3). Overall, with 20% error and varying 
sample sizes and numbers of concentrations from each subject, percent absolute prediction 
errors were lowest for NONMEM, followed by Pmetrics, and then Monolix (P<0.001 for 
all comparisons). 
When the modeling programs were tested with datasets that featured 80% error, 
bias increased and precision decreased (Figure 6.3B and Table 6.1). Pharmacokinetic 
parameter estimates were positively biased for both Monolix and NONMEM, whilst 
Pmetrics pharmacokinetic parameter estimates were negatively biased (P<0.001 for all 
comparisons). Increasing the number of concentrations from each subject decreased 
percent absolute prediction errors (P<0.001). Additionally, increasing the number of 
subjects slightly decreased percent absolute prediction errors (P=0.05). With 80% error, 
percent absolute prediction errors were lowest for NONMEM, followed by Monolix, and 
then Pmetrics (P<0.001 for all comparisons). 
 
Incorrectly-Specified Models without Covariates 
 In Figures 6.4A and 6.4B the normalized values of the pharmacokinetic parameter 
estimates are presented for incorrectly-specified models that did not incorporate the 
influence of weight on clearance or the volume of distribution. Monolix, NONMEM, and 
Pmetrics clearance estimates were positively biased, whereas the volume of distribution 
estimates were unbiased. Notably however, the range of normalized values for Pmetrics 
was considerably larger than that observed for Monolix and NONMEM, which may be 
































































































































































Figure 6.4. Clearance (A) and volume of distribution (B) parameter estimates using 
incorrectly-specified models without covariates. For each parameter, the estimated value 
was normalized by the true value. The gray horizontal line depicts the true normalized 
values (equal to 1). The box plots depict the 25th, 50th, and 75th percentiles. The vertical 
lines extending from each boxplot extend to 1.5 times the interquartile range, with values 
beyond this point denoted by unfilled circles. 
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 When the incorrectly-specified models were applied to simulated datasets with 20% 
error, the results of all three modeling programs were significantly biased (P<0.001 for 
all).  Neither increasing the number of concentrations per subject (P=0.2) nor increasing 
the sample size (P=0.3) reduced the bias. As seen in Table 6.2, the magnitude of the bias 
was comparable among all three modeling programs (P>0.1 for all comparisons). 
Similarly, increasing the number of concentrations per subject (P=0.7) and increasing the 
sample size (P=0.2) did not improve the precision of the parameter estimates. The precision 
of the pharmacokinetic parameter estimates was slightly higher for NONMEM than for 
Monolix (P=0.02) (Figure 6.5A); however, the precision of the pharmacokinetic parameter 
estimates obtained with Pmetrics was substantially higher than that observed with 
NONMEM and Monolix (P<0.001 for both). 
Similar to the findings observed with 20% error, when the incorrectly-specified 
models were applied to datasets with 80% error, all three modeling programs yielded 
significantly biased pharmacokinetic parameter estimates (P<0.001 for all). Larger sample 
sizes (P<0.001) and increased numbers of samples obtained from each subject (P=0.01) 
were associated with increased bias. Pmetrics was substantially more biased than both 
NONMEM and Monolix (P<0.001 for both); however, NONMEM was slightly more 
biased than Monolix (P=0.002). The precision of the pharmacokinetic parameter estimates 
was not affected by changes in the number of samples obtained from each subject (P=0.7). 
In contrast, precision decreased with larger sample sizes (P<0.001). With the incorrectly-
specified models, the median percent absolute prediction error was highest for Pmetrics, 
followed by NONMEM, and then Monolix (Figure 6.5B). 
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Table 6.2. Bias and precision of the estimated population pharmacokinetic parameter 
values obtained using Monolix, NONMEM, and Pmetrics for the incorrectly-specified 
models without covariates. 
 Monolix NONMEM Pmetrics 





(0.6% to 31.7%) 
17.2% 
(0.1% to 67.3%) 
29.9% 
(-5.8% to 90.7%) 
Median percent 
absolute prediction 
error (IQR) b 
16.5% 
(3.9% to 64.1%) 
17.3% 
(3.8% to 67.3%) 
32.7% 
(13.8% to 90.7%) 





(0.0% to 62.1%) 
19.7% 
(-0.4% to 67.4%) 
24.8% 
(-6.3% to 90.4%) 
Median percent 
absolute prediction 
error (IQR) b 
19.6% 
(5.9% to 62.1%) 
23.0% 
(5.8% to 67.4%) 
34.5% 
(14.8% to 90.4%) 





(-0.8% to 58.0%) 
21.2% 
(-1.0% to 66.5%) 
31.2% 
(-2.9% to 101.5%) 
Median percent 
absolute prediction 
error (IQR) b 
21.9% 
(7.5% to 58.0%) 
25.1% 
(7.7% to 66.6%) 
38.3% 
(16.3% to 101.5%) 





(-1.9% to 55.4%) 
20.0% 
(-2.3% to 66.2%) 
38.3% 
(-0.2% to 114.9%) 
Median percent 
absolute prediction 
error (IQR) b 
22.4% 
(8.5% to 55.4%) 
26.7% 
(8.9% to 66.2%) 
42.6% 
(17.5% to 114.9%) 
a Percent prediction error is a measure of bias. 







































































































































































Across a wide range of simulated error terms, sample sizes, and varying numbers 
of concentrations obtained from each subject, with correctly-specified covariate models, 
the three population pharmacokinetic modeling programs tested were modestly biased 
(median percent prediction error of 32%) and imprecise (median percent absolute 
prediction error of 37%). Several consistent themes emerged for all three population 
pharmacokinetic modeling programs, including a decrease in bias with larger numbers of 
concentrations obtained from each subject and a more modest decrease in bias with larger 
sample sizes for correctly-specified models. Additionally, increasing the number of 
concentrations obtained from each subject, but not larger sample sizes, improved the 
precision of the pharmacokinetic parameter estimates. Despite these consistent findings 
across all three population pharmacokinetic modeling programs, relative strengths and 
weaknesses were also identified with each of the modeling programs parameter estimation 
algorithms tested. 
As expected, the stochastic approximation EM algorithm implemented in Monolix 
yielded less biased parameter estimates than those obtained with the FOCEI method in 
NONMEM and the NPAG method in Pmetrics, with the correctly-specified covariate 
model. Also as expected, Monolix pharmacokinetic parameter estimates were less precise 
than those obtained with the FOCEI method implemented in NONMEM. Monolix 
performed equally as well as NONMEM but considerably worse than Pmetrics at 
identifying model misspecification, as evidenced by relatively low percent prediction and 
percent absolute prediction errors with the incorrectly-specified model. Nevertheless, 
Monolix is freely available to students and academics and features a user-friendly graphical 
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interface. 
The FOCEI algorithm implemented in NONMEM was more precise than the EM 
algorithm implemented in Monolix and the NPAG algorithm implemented in Pmetrics. 
Additionally, NONMEM’s FOCEI algorithm was less biased than Pmetrics’ NPAG 
algorithm when applied to correctly-specified models. Similar to Monolix, NONMEM 
struggled to identify misspecified models; however, unlike Monolix, NONMEM requires 
an annual license and does not come packaged with a graphical interface. 
The NPAG algorithm implemented in Pmetrics yielded more biased and imprecise 
pharmacokinetic parameter estimates than both Monolix and NONMEM when applied to 
incorrectly-specified models that did not incorporate the influence of weight on clearance 
or the volume of distribution. However, when the NPAG algorithm was applied to 
correctly-specified models, the pharmacokinetic parameter estimates were more biased 
than those obtained with Monolix and NONMEM. With correctly-specified models, 
similar precision was achieved with Pmetrics and Monolix; however, Pmetrics’ NPAG 
algorithm yielded less precise parameter estimates when compared with NONMEM’s 
FOCEI algorithm. As with Monolix, Pmetrics is available at no cost to students and 
academics. Although Pmetrics is not bundled with a standalone graphical interface, it is 
interfaced through the open source statistical software program R. 
This study is limited by its use of simulated drug concentration time profiles, which 
cannot possibly capture the breadth of biological processes involved in human 
pharmacokinetic studies. Nevertheless, this simulation-based design was adopted so that it 
would be possible to compare the pharmacokinetic modeling programs’ results with 
known, true values, which are unknowable in clinical pharmacokinetic studies. 
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Additionally, the metrics used to benchmark these population pharmacokinetic modeling 
programs included the percent prediction error and the percent absolute prediction error; 
however, alternative metrics exist. Nevertheless, the percent prediction error and the 
percent absolute prediction error were used as they provide a cogent way to simultaneously 
compare the results of different pharmacokinetic parameter estimation algorithms 
employed in different modeling programs across a wide range of study designs. A further 
limitation of this study is that the length of time required to run the models was not 
captured; however, no modeling program took longer than 1 hr to run a single model. 
In pharmacokinetic simulations with study designs mimicking those observed in 
previously published clinical trials, the bias and precision of three of the most commonly 
used population pharmacokinetic modeling programs was approximately 30-35%. This 
suggests that additional efforts are needed to develop less biased and more precise 
pharmacokinetic parameter estimation algorithms. However, these simulations revealed 
relative strengths and weaknesses of Monolix, NONMEM, and Pmetrics, which should be 
considered when attempting to identify the most appropriate estimation algorithm and 
modeling program for each project. Across all three population pharmacokinetic modeling 
programs, bias was found to decrease substantially with the collection of additional 
concentrations from each subject, and to a lesser degree with increasing sample sizes. In 
contrast, precision was found to improve only with a greater number of concentrations 
collected from each subject. 
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 By and large, clinical pharmacology – and population pharmacokinetics in 
particular – remains a field that is ripe for investigation as many questions are still 
unanswered despite decades of experience using well-established methods and modeling 
programs. In this dissertation, we revisited the clinical utility of population 
pharmacokinetic modeling, along the way challenging conventional dosing strategies for 
vancomycin in preterm neonates and zolpidem among severely burned children, in an effort 
to shed light on the importance of conducting clinical pharmacokinetics studies. 
 Ideally, population pharmacokinetic studies should be designed to reflect clinical 
practice and involve participants who are similar to those for whom the study’s results are 
intended to be applied to.  Unfortunately, there is a dearth of well-designed pediatric 
population pharmacokinetic studies, which has hampered the development of safe and 
effective dosing regimens for many medications that are used in children’s hospitals around 
the world.[1]  Although multiple factors likely underlie the shortage of pediatric population 
pharmacokinetic studies, the perception that pediatric studies are costly, time consuming, 
and logistically challenging is likely one of the leading factors.[2] To dispel this fallacy, 
we leveraged vancomycin therapeutic drug monitoring data from two vulnerable pediatric 
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populations to provide evidence supporting the safety and effectiveness of current dosing 
regimens for children with cystic fibrosis and validated new dosing regimens that more 
reliably achieve therapeutic targets for preterm neonates with invasive bacterial 
infections.[3, 4] Additionally, we identified evidence of sub-therapeutic dosing among 
severely burned children treated with the sleep-enhancing agent zolpidem in a prospective 
clinical trial.[5] 
It is of equal – if not more – importance to also assess the validity of population 
pharmacokinetic modeling programs against a true gold standard, thereby ensuring that the 
recommendations that are developed from population pharmacokinetic studies are 
unbiased and accurate. Toward this effort, we developed a simulation-based framework for 
benchmarking the bias and accuracy of population pharmacokinetic parameter estimates 
and confirmed the average bias and precision of three of the most commonly used 
population pharmacokinetic modeling programs to be approximately 30-35%.  This finding 
suggests that although these models may perform adequately for drugs with wide 
therapeutic windows, additional research is needed to improve the predictive performance 
of the pharmacokinetic parameter estimation algorithms employed in these programs, 
particularly when they will be applied to characterize the pharmacokinetic properties of 
drugs with narrow therapeutic windows. 
The main contribution of our simulation-based benchmarking paradigm was 
identification of the relative strengths and weaknesses of the pharmacokinetic parameter 
estimation algorithms implemented in the three modeling programs we studied. These 
differences in the performance characteristics of the estimation algorithms ought to be 
considered when designing population pharmacokinetic studies.  For first-in-human studies 
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or trials involving patient populations in which the investigational drug has not been 
studied before, gaining insight into the factors that influence the drug’s pharmacokinetics 
may be more important than predictive accuracy.  In cases such as these, one might 
consider using the NPAG algorithm implemented in Pmetrics, as it performed best in 
identifying ill-specified covariate models.  Conversely, for clinical use (e.g., therapeutic 
drug monitoring), the correct covariate-model structure has likely already been defined 
previously and the goal is instead to accurately predict a patient’s pharmacokinetic 
parameters, for which Monolix’s EM algorithm or NONMEM’s FOCEI algorithm may be 
preferred. 
This preliminary work sets the stage for many additional directions of future 
investigation, including those of a practical and a theoretical nature.  We are currently 
recruiting participants as part of a clinical trial that will compare target rates of treatment 
failure and nephrotoxicity among neonates who are dosed according to the vancomycin 
model described in Chapter 4 as compared with historical controls at the University of Utah 
and Stanford University.  Additionally, we submitted a grant requesting funding to perform 
a pharmacokinetic-guided dosing study of zolpidem among children with severe burn 
injuries who are cared for in the Shriners’ network of children’s hospitals.  From a more 
theoretical standpoint, we believe that the simulation-based framework for benchmarking 
population pharmacokinetic parameter estimation algorithms described in this dissertation 
can be applied to many additional interesting questions, which include (but are not limited 
to): 
1) Do the same patterns identified in Chapter 6 hold true with more complex 




2) Which algorithms perform best for pharmacodynamic analyses?  What are the 
influential factors in pharmacodynamic analyses that affect bias and precision 
and to what extent can these be controlled for with optimal clinical trial design? 
3) Which algorithms perform best for mixture models?  Under what circumstances 
is bias minimized and precision maximized? 
4) How much of an effect do date and time errors in dosing and concentration 
records have on pharmacokinetic parameter estimates?  Does the effect vary 
with different estimation algorithms? 
Overall, this dissertation lays the foundation for a permanent re-assessment of the 
role of population pharmacokinetic analyses in drug development and clinical practice.  
The clinical utility demonstrated in the three real-world case studies presented in Chapters 
3, 4, and 5 should foster the development of new pharmacokinetic parameter estimation 
algorithms that can further improve the predictive accuracy and interpretability of 
population pharmacokinetic analyses.  Additionally, the novel simulation-based 
benchmarking framework that we developed here can easily be extended to provide a true 
gold standard to guide the development of new algorithms.  With clinical impact driving 
the development of these new algorithms, it should be understood that these models cannot 
be thought of as ‘black boxes’, but rather they must be thought of as rational tools that can 
provide insights into the underlying biology and pharmacology hidden within the data, 
whilst simultaneously yielding accurate pharmacokinetic predictions that may be used to 




As we look to the future and consider the situations in which population 
pharmacokinetic models may be most useful, it is worth noting that the factors influencing 
pharmacokinetic variability differ between drugs, disease states, and the presence / absence 
of other co-prescribed medications. Many drugs feature wide therapeutic windows for 
which a single well-designed population pharmacokinetic study may be sufficient to 
establish an effective and safe range of exposures. For drugs such as these, population 
pharmacokinetic modeling can facilitate the development of dosing regimens designed to 
reliably achieve the target exposure range for the vast majority of patients. 
The situation is more complicated for medications that are used in the hospital 
setting as these often feature narrow therapeutic windows and may be administered to 
critically-ill patients. In situations such as these, a one size fits all approach to dosing is 
unlikely to be maximally efficacious and safe. Instead, collection of one or two samples to 
measure drug concentrations from an individual patient may be performed to develop a 
personalized pharmacokinetic model. Moreover, these additional concentrations can be 
leveraged to better inform the dosing recommendations for the population at large via 
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$PROBLEM   Neonatal vancomycin population pharmacokinetic model 
                               
$INPUT C ID TIME AMT DV MDV RATE WT SCR JSCR PMA PNA TYPE 
DOSE 
 
  ; ID  =  Subject identifier 
  ; TIME  =  Time (measured in hours) 
  ; AMT  =  Dose amount (mg) 
  ; DV  =  Drug concentration (mg/L) 
  ; MDV  =  Missing dependent variable 
  ; RATE  =  Infusion rate (mg/hr) 
  ; WT  =  Weight (kg) 
  ; SCR  =  Serum creatinine concentration (mg/dL) 
  ; JSCR  =  Linear conversion of enzymatic SCr to  
the Jaffe method 
  ; PMA  =  Postmenstrual age (weeks) 
  ; PNA  =  Postnatal age (days) 
  ; TYPE  =  Drug concentration type (0 = trough,  
1 = peak) 
  ; DOSE  =  Daily dose (mg/day) 
 
$DATA NEONATAL_VANCO_DATA.CSV IGNORE=C 
$SUB  ADVAN1 TRANS2 
 
$PK 
  TH1  =  THETA(1) 
  TVCL =  TH1 * (WT/2.9)**0.75 * 
(1/(1+(PMA/THETA(3))**(-(THETA(4))))) * 
(1/JSCR)**(THETA(5)) 
  CL  =  TVCL * EXP(ETA(1)) 
  TH2  =  THETA(2) 
  TVV  =  TH2 * (WT/2.9)**1.0 
  V  =  TVV * EXP(ETA(2)) 
  TM50 =  THETA(3) 
  HILL =  THETA(4) 
  CR  =  THETA(5) 
  S1  =  V 
  AUC  =  DOSE / CL 
 
IF(AMT.GT.0) THEN 
  TDOS =  TIME 










  0.345  FIXED  ; Population clearance 
  1.75  FIXED  ; Population volume of distribution 
  34.8  FIXED  ; TM50 
  4.53  FIXED  ; Hill coefficient 
  0.267  FIXED  ; Creatinine effect 
 
$OMEGA BLOCK(2) FIXED 
  0.0465 
  0.00734  0.0119 
 
$SIGMA 
  0.0421 FIXED  ; Proportional error 
  1.168 FIXED  ; Additive error 
 
$ERROR 
  A1  = A(1) 
  Y  = F + F * ERR(1) + ERR(2) 
  IPRED = F 
 
$ESTIMATION METHOD = 1 INTERACTION MAXEVAL = 0 POSTHOC 
$TABLE ID TIME DV MDV CL V TH1 TH2 TM50 HILL CR WT PMA JSCR AUC 






















  ambien_final.mlxtran 
 
DATA:  
  path = "%MLXPROJECT%/", 
  file = "zolpidem_data.csv", 
headers = {ID, TIME, Y, MDV, AMT, COV, COV}, 
  columnDelimiter = "," 
 
VARIABLES:  
  THIR [use = cov], 
  WT, 
  t_WT = log(WT) [use = cov,  centeredBy = mean] 
 
INDIVIDUAL:  
  Cl = {distribution = logNormal, covariate = t_WT, iiv = yes}, 
  Q = {distribution = logNormal, iiv = yes}, 
  V1 = {distribution = logNormal, covariate = THIR, iiv = yes}, 
  V2 = {distribution = logNormal, iiv = yes}, 
  ka = {distribution = logNormal, iiv = yes} 
 
STRUCTURAL_MODEL:  
  file = "oral1_2cpt_kaClV1QV2", 
  path = "%MLXPATH%/libraries/PKLibrary", 
  output = {Cc} 
 
OBSERVATIONS:  
  y1 = {type = continuous, prediction = Cc, error = combined1} 
 
TASKS:  
  ; settings 
  globalSettings = { 
    withVariance = no, 
    settingsGraphics = "%MLXPROJECT%/ambien_final_graphics.xmlx", 
settingsAlgorithms = 
"%MLXPROJECT%/ambien_final_algorithms.xmlx", 
    resultFolder = "%MLXPROJECT%/ambien_final"}, 
  ; workflow 
  estimatePopulationParameters( 
    initialValues = { 
      pop_Cl = 1, 
      beta_{Cl,t_WT} = 0.75 [method = FIXED], 
      pop_Q = 1, 
      pop_V1 = 1, 
      beta_{V1,THIR} = 0, 
      pop_V2 = 1, 
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      pop_ka = 0.18 [method = FIXED], 
      a_y1 = 1, 
      b_y1 = 0.3, 
      omega_Cl = 1, 
      omega_Q = 1, 
      omega_V1 = 1, 
      omega_V2 = 1, 
      omega_ka = 1 
    }), 
estimateFisherInformationMatrix(method = {linearization}), 
estimateIndividualParameters(method = {conditionalMode}), 
estimateLogLikelihood(method = {linearization}), 
displayGraphics(), 
 
   
 Reprinted with permission from Stockmann, C. et al. Relationship Between 
Zolpidem Concentrations and Sleep Parameters in Pediatric Burn Patients. Journal of Burn 
Care & Research 36, 137-144, doi:10.1097/BCR.0000000000000164 (2014). Copyright 
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